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     Cochlear implants (CIs) are the preferred treatment for patients with moderate to 
profound sensorineural hearing loss. However, increasing numbers of CI recipients have 
remaining hearing that must be protected from insertion trauma. Local delivery of 
therapeutics could protect these initially viable inner ear sensory cells. This dissertation 
characterizes multicompartmental microparticles and their use for inner ear drug delivery. 
     The first part of this dissertation involved the determination of preferred design and 
infusion parameters for local drug delivery in the cochlea using multicompartmental 
microparticles. Parameters were classified as preferred if their modulation increased 
visualization of microparticles within cochlear tissues. Preferred parameters were 
associated with particle design (fluorescence intensity), particle infusion protocol 
(composition of delivery matrix), or tissue processing and post-harvesting (non-vascular 
tissue fixation). 
     In the next part of the dissertation in vivo microparticle persistence, distribution, and 




model. Imaging of cochlear cross sections demonstrated the presence of microparticles 
for at least 7 days post infusion. Functional analysis with auditory brainstem response and 
histopathological analysis demonstrated that an infusion of non-drug loaded particles 
could be delivered with limited negative impact on hearing and cell viability and did not 
induce an immune response.  
     The final part of the dissertation evaluated in vitro and in vivo pharmaceutical release 
from multicompartmental microparticles. Incorporation and sequestration of Piribedil, an 
anti-excitotoxic agent, within a particular microparticle compartment was confirmed. In 
vitro microparticle assessment demonstrated sustained Piribedil release on the order of 
weeks which is suitable for intracochlear drug delivery. Analysis of perilymph obtained 7 
days after in vivo infusion of Piribedil-loaded particles identified the pharmaceutical at 
detectable levels. For the first time, release of therapeutic levels of a pharmaceutical from 
an intracochlear particle system was demonstrated. This work provides the first 
evaluation of multi-release particles for local drug release in the cochlea for both in 
vitro and in vivo environments; defines the challenges to efficacious use of these drug 
carriers for modifying inner ear function; and identifies a research pathway that may 






Chapter 1                                                                                                        
Introduction: Cochlear Trauma and Drug Delivery 
1.1. Impact of Hearing Loss 
     Approximately 36 million Americans suffer from hearing impairment (Donahue, 
2010). These impairments influence many facets of an individual’s life from social 
interactions to employment opportunities (Mohr et al., 2000). While those unaffected by 
hearing loss may take the use of this sense for granted, the process of hearing is 
multifaceted and complex.  The ear is comprised of three distinct parts: the outer, middle, 
and inner ears. In normal hearing processes (Figure 1-1), sound waves enter the outer ear 
and then induce bone vibrations in the middle ear. The propagation of vibrations in the 
middle ear stimulate fluid movement in the inner ear (cochlea) which in turn stimulates 
hair cell vibrations that result in electrical signals that subsequently are sent to the 
auditory nerve cells. These nerve cells carry the electrical signal from the cochlea to the 
brain, eventually to the auditory cortex, which enables the initial sound to be perceived 
(Waltzman, 2006).  However in individuals with hearing impairments, at least one part of 
this hearing cascade is disrupted. The causes of hearing loss are varied ranging from 
autoimmune diseases and infection to physical injury and environmental stress, including 
noise-induced trauma (Poe & Pyykkö, 2011; Swan et al., 2008). As a result, a wide 
variety of treatment options are available to hearing impaired patients depending on the 
severity of their impairment with options ranging from hearing aids to cochlear implants. 
Before understanding how these options work, it is important to become familiar with 




organ with membranous and bony components.  In humans, there are 2.5 turns and in 
guinea pigs, a common auditory research model, there are 4 turns. There are three 
chambers in the cochlea: the scala tympani, scala media, and scala vestibuli. Each of the 
respective chambers of the cochlea is filled with fluid. The fluid in the scala tympani and 
scala vestibuli is called perilymph and consists of a relatively high concentration of 
sodium ions. Conversely, endolymph, the fluid in the scala media, has a relatively high 
concentration of potassium ions. There is communication between the scala tympani and 
scala vestibuli particularly at the apex (the top of cochlea) in an area called the 
helicotrema. The chambers are separated by the basilar membrane, composed of 
mesothelial cells, and Reissner’s membrane, composed of epithelial cells (Raphael & 
Altschuler, 2003).  
     The organ of Corti, the primary hearing organ, is located in the scala media. Hair cells, 
the sensory transduction cells of the cochlea, reside in the organ of Corti and thereby the 
scala media. There are three rows of outer hair cells and one row of inner hair cells. Outer 
hair cells aid in amplification of the sound wave providing sensitivity and selectivity. 
Inner hair cells act as mechanotransducers converting the mechanical energy imparted by 
the fluid movement to initiate depolarization of spiral ganglion neurons (SGNs), a type of 
auditory nerve cell. The depolarization of these cells results in the generation of an 
electrical signal that can be transmitted to the brain to enable the perception of sound 
(Raphael & Altschuler, 2003). The cochlea has two membrane covered openings to the 
middle ear, the oval window and the round window, which serve important functions. 
The oval window formed largely by the foot plate of the stapes, covers the opening of the 




into direct contact with the bones of the middle ear. The round window is located at the 
base of the scala tympani, at the other end of the perilymphatic canal. The round window 
membrane functions to relieve pressure in the scala tympani by moving in response to a 
pressure gradient created by fluid movement.  
     The cochlea is tonotopic meaning that there is a correlation between function and 
cochlear location; specifically different portions of the cochlea are more readily activated 
by different frequencies of stimulation. The basal portion of the cochlea is most 
responsive to high frequency sounds while the apex is most responsive to low frequency 
(low pitch) sounds, Figure 1-3. Both the basilar membrane and the outer hair cells 
contribute to the tonotopic nature of the cochlea. The basilar membrane vibrates in 
response to pressure differences across the scala media, however the frequency of the 
sound source determines the location of maximal displacement of the membrane. From 
the base of the cochlea to the apex the basilar membrane thickens and widens while the 
length of outer hair cells increases. As a whole the structure from base to apex varies 
systematically in mass and stiffness, with the greatest stiffness and least mass at the base.  
Thus the resonance varies continuously from base to apex, with the base most responsive 
to high frequencies.  Hearing aids are external devices that augment hearing by simply 
amplifying incoming sounds before they enter the ear canal at which point the normal 
hearing cascade occurs. Since hearing aids require functioning sensory and neural cells, 
they are not the preferred option for individuals with substantial damage to these cell 
populations.  Cochlear implants work by bypassing sensory cells and providing direct 
electrical stimulation from their placement in the scala tympani to the auditory nerve cells 




Generally implants consist of a microphone, auditory processor, implant coil, and 
electrode array as seen in Figure 1-5. Cochlear implants are often inserted through the 
round window membrane or via a cochleostomy into the scala tympani. External sounds 
are amplified by the microphone and auditory processor before transmission to the 
implant coil. The implant coil propagates an encoded electrical signal to the electrode 
array which is used to stimulate nearby auditory neurons.  While hearing aids and 
cochlear implants can provide great benefit, they are far from perfect and in need of 
improvement, leading researchers and clinicians to strive to combine technologies and 
techniques to enable patients to experience a therapeutic benefit greater than the 
respective interventions could provide separately.  A major strategy for the future will 
include the combination of biotechnological (devices) and pharmaceutical treatment. 
1.2. Causes (Sensorineural) & Hair Cell Loss and Intervention Strategies to 
Preserve Hair Cells 
     There are two primary types of hearing loss, conductive and sensorineural. Conductive 
hearing loss is characterized by damage to the outer and/or middle ear while 
sensorineural hearing loss is characterized by damage to the inner ear. Common 
treatment for conductive hearing loss is surgery and/or hearing aids. Treatment for 
sensorineural is more complex and the current treatment standard for moderate to severe 
pathology is the cochlear implant (CI). Cochlear implantation can result in hair cell loss 
in addition to the loss of peripheral processes of the auditory nerve as a result of physical 
trauma induced via device insertion. Eshraghi et al. demonstrated that even soft insertions 
with electrodes designed to minimize damage to the cochlea are likely to induce injury at 




van de Water, 2006). Cochlear insult is believed to induce bursting of the peripheral 
process and the formation of reactive oxygen species (ROS). Therefore, the inhibition 
ROS formation via pharmaceuticals such as anti-oxidants appears to be a promising 
therapeutic route (Ohlemiller et al., 1999). The utility of this approach was evident in a 
study by Duan et al. (Duan, 2004). In this work, sensorineural hearing loss was induced 
in rats via high levels of impulse noise (similar to that that may be encountered with the 
use of firearms or as a result of exposure to industrial equipment).  Prior to and after 
noise exposure, rats were treated with doses of the antioxidant, N-L-acetylcysteine 
(NAC), to assess the ability of this treatment to protect the cochlea from oxidative 
damage. Rats which did not receive antioxidant treatment served as the control and 
auditory-evoked brainstem responses (eABRs) were used to evaluate hearing loss. Rats 
which received a total of three NAC doses (one given an hour before noise insult, one 
given immediately following noise insult, and one given three hours after insult) were 
found to exhibit decreased hearing loss as compared to the controls thereby suggesting 
the protective value of antioxidant therapy on the cochlea.  
     Additionally, tumor necrosis factor α, a known mediator of cochlear inflammation, is 
released post-injury and as a result of this release induces hair cell loss (Satoh, 2002). In 
this instance, the use of a steroid such as dexamethasone (Dex) has shown promise for the 
prevention of hair cell loss as a result of noise-induced and physical trauma (Bin Wang, 
2013; James DP & SJ, 2008). For example, direct infusion of dexamethasone into the 
guinea pig cochlea prior to noise-induced trauma was shown to have a protective effect 
(Takemura et al., 2004). Specifically, guinea pigs were treated with various doses of Dex 




then exposed to a 120 dB noise at a frequency of 4kHz for 24 hours. As compared to 
those that received AP, a dose-dependent response in the attenuation of hair cell damage 
was noted.  In another guinea pig animal model, the ability of corticosteroids to attenuate 
hair cell loss after cochlear electrode implant trauma was evaluated (A. a. Eshraghi et al., 
2007). The authors inserted a cochlear electrode into guinea pigs who then did not 
receive further treatment or who received an infusion of either AP or Dex respectively for 
eight days after implantation. The contralateral ear of each guinea pig tested served as an 
internal control and the hearing loss of the implanted ear was compared to that of the 
control ear. ABR results show that by day 30 ears in animals receiving Dex infusions 
after electrode insertion did not demonstrate significant hearing loss as compared to their 
contralateral controls irrespective of the frequency tested. Moreover significant hearing 
loss was noted in animals who received infusions of AP or no treatment at all thus 
indicating the potential of this strategy in attenuating hearing loss caused by cochlear 
implantation.    
1.3. Importance of IHC-AN Connections 
     One mechanism implicated in neural cell death post implantation is excitotoxicity in 
postsynaptic afferent fibers of the auditory nerve. There are two modes of excitotoxicity 
in the cochlea: 1) deterioration of the inner hair cell-auditory nerve (IHC-AN) connection 
induced by inner hair cell apoptosis or 2) bursting of auditory nerve processes in response 
to excess glutamate release from the IHC onto the IHC-AN synapse (A. A. Eshraghi, and 
T. R. van de Water, 2006). One of the dominant approaches in the field has been to 
attenuate excitotoxicity by preserving IHCs and subsequently the IHC-AN connections 




reconnection of neuronal processes with IHCs following insult as long as the IHCs were 
maintained, leading to the assumption that the presence of IHCs indicated the presence of 
functional IHC-AN connections. However recent studies by Kujawa indicate that 
reconnection may not be as efficient as initially thought with significant losses of IHC-
AN connections observed even when IHCs are preserved (Harrison, 2011; 2009). 
1.4. Pharmaceutical Intervention for Cochlear Pathologies: Focus on Anti-
Excitotoxicity Therapy 
 
     Anti-oxidants, corticoids/anti-inflammatory agents, and anti-excitotoxic agents are all 
classes of pharmaceuticals that have been investigated as interventions for ameliorating 
inner ear pathologies. Corticosteroids are used to reduce inflammation (Kitajiri, 2002). 
The primary function of anti-oxidant administration to the cochlea is to enable these 
agents to be used as scavengers of reactive oxygen species (ROS) which are toxic to the 
cellular and sub-cellular structures of the cochlea, particularly hair cells. Anti-oxidants 
also directly inhibit the apoptotic pathways activated by the presence of reactive oxygen 
species. Anti-excitotoxic agents are delivered to the cochlea to promote survival of neural 
cells and inner hair cell auditory nerve (IHC-AN) synapses. These drugs inhibit the 
sensitivity of nerve receptors to the excessive neurotransmitter release that occurs in 
pathological conditions following trauma. Glutamate is the primary neurotransmitter that 
is overreleased and in the absence of inhibition, auditory neurons are overstimulated 
causing calcium channels to be open excessively leading to an excessive influx calcium. 
This disproportionate calcium influx is accompanied by an influx of water into the nerve 
leading bursting of peripheral processes which results in deafferentation of the neuron 




would be those that act to decrease responsiveness to or the release of glutamate. Further 
rationale for selecting glutamate inhibitors is that it acts as a non-competitive antagonist 
and thereby would not interfere with the hearing cascade under normal conditions.  
Previous studies using competitive inhibitors have demonstrated decreased excitotoxicity 
in the auditory nerve in the presence of the aforementioned inhibitors albeit in the 
presence of serious side effects such as hearing loss, psychosis, and vomiting (Jager, 
2000; Kitajiri, 2002).  Potential non-competitive anti-excitotoxic agents are Memantine 
and Piribedil. Memantine and Piribedil are both neurotrophic agents that have previously 
demonstrated potential to inhibit excitotoxicity in the ear. Piribedil, a dopamine agonist, 
acts chemically to inhibit the inner hair cell auditory nerve (IHC-AN) synapse of afferent 
dendrites while Memantine, a N-Methyl-D-aspartic acid  (NMDA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
receptor antagonist physically prevents binding of stimulatory glutamate to prevent 
synaptic activity (d'Aldin, 1995; Oestreicher, 1998). A previous study with Piribedil 
utilizing intracochlear delivery of free drug prior to noise exposure found that treatment 
resulted in decreased excitotoxicity of the auditory nerve as evidenced by the lack of 
swelling and bursting of the peripheral processes (Oestreicher, 1998). In addition, there 
was attenuation of the number of IHC-AN connections lost after noise exposure in the 
presence of noise (d'Aldin, 1995). Further d’Aldin and colleagues demonstrated that this 
infusion of free drug reduced the compound action potential (CAP) amplitude after noise 
exposure without impacting the cochlear microphonic (hair cell) potential, which 
indicates that the treatment provided improved IHC-AN connection survival following 




1.5. Challenges of Drug Delivery to the Cochlea 
     While pharmaceuticals have the potential to positively impact cochlear health, they 
must first reach the cochlea in order to do so. Delivering drugs to the cochlea is complex 
because numerous challenges and obstacles impede therapeutic delivery to the cochlea. 
One of the most significant challenges is bypassing the blood-labyrinth barrier (BLB) 
(Swan et al., 2008). Similar in function to the blood-brain barrier, the BLB serve as a 
barrier between substances in general circulation and inner ear fluids thus limiting the 
diffusion of drugs and molecules from the vessels supplying the cochlea to the cochlear 
compartment. The efficacy of this barrier is derived from the tight junctions of which the 
BLB is comprised as these junctions help maintain a distinct chemical composition of the 
inner ear that differs from that which is found in the blood circulation.  Another cochlear 
characteristic that imposes challenges on cochlear drug delivery is the limited diffusion of 
agents within the cochlea. There is negligible fluid flow in the cochlea; therefore drug 
dispersion is primarily by passive diffusion (Alec N. Salt & Plontke, 2009). This can 
result in a concentration gradient along the cochlea with cochlear locations and fluids 
distal from the infusion site receiving small amounts or essentially none of the intended 
therapeutic. 
     Though there are inherent cochlear characteristics that inhibit drug delivery, the drugs 
themselves can be limiting factors. In order to be effective, a drug must persist in vivo 
long enough to reach its target destination and/or deliver therapy for a defined time 
period (Chen, 2010). Therefore, the drug half-life, or the time it takes for half of a given 
dose to be eliminated from the body, is an important consideration. Therapeutic efficacy 
in cochlear delivery would be enhanced if the half-life of potential therapeutics were 




side effects that may hinder their use. Thus it would be advantageous to limit the number 
and/or severity of a drug’s side effects.  The carrier used to deliver the drug also plays an 
important role in drug delivery particularly as it relates to immune response. The carrier 
should be designed such that it is unlikely to elicit a significant immune response. Should 
a significant immune response occur, immune cells such as macrophages may uptake the 
drug carrier, eliminating it from the cochlea which prevents efficacious drug delivery. 
1.6. Drug Delivery (Systemic vs. Local) 
     The mode of delivery is also crucial to evaluating the efficacy of therapeutic 
approaches. Pharmaceuticals have been delivered to the cochlea by both local and 
systemic routes (Le Prell, 2007; Yamagata, 2004). Early on, systemic delivery was the 
primary mode of drug delivery to the cochlea and drugs could be administered either 
orally or intravenously (Zou et al., 2010). However, there are numerous drawbacks that 
inhibit the effectiveness of systemic delivery. One of the most prominent limitations of 
systemic delivery is that therapeutic levels of the drug may never reach the cochlea. This 
can occur for a myriad of reasons including the blood-labyrinth barrier, clearance of the 
drug from systemic circulation, and drug release from a carrier prior to arrival at the site 
of interest (Alec N. Salt & Plontke, 2009). Furthermore, systemic delivery is more likely 
to lead to unwanted side effects as there is increased opportunity for the drug to act on 
other systems.  
     Local delivery of therapeutics to the inner ear is preferred in order to bypass the 
blood-labyrinth barrier and enable drug concentrations within the cochlea to reach the 
levels required to provide therapeutic efficacy while minimizing side effects (Hendricks 




to locally deliver drugs to the inner ear. These methods may be further divided into two 
categories of delivery: intratympanic and intracochlear (Rivera T et al., 2012). 
Intratympanic delivery involves the placement of pharmaceuticals into the middle ear and 
relies on diffusion across the round window membrane for agents to reach the inner ear 
while intracochlear delivery is the direct placement of drugs into the inner ear fluids. 
Since cochlear implantations are intracochlear surgical procedures, the access provided to 
cochlear fluid compartments presents a window of opportunity for local delivery of 
therapeutic agents with explicit clinical applicability.  
     The composition of the drug delivery vehicle is important to its intended application 
and the use of polymers is attractive since these materials enable tailoring of properties 
such as elasticity, hydrophillicity/hydrophobicity, biocompatibility, degradation, and cell 
targeting through the combination of various monomers or surface modification. 
Additionally, a broad range of polymer materials are utilized in cochlear drug delivery 
including both natural and synthetic materials (Anderson, 2009; Horie et al., 2010; 
Noushi, 2005; Alec N. Salt et al., 2011; Shayanne A. Lajud & Samudra Sanyal, 2013).  
Intratympanic delivery which exploits the permeability of the round window membrane 
(RWM) is a common delivery mechanism when delivery from biodegradable hydrogels 
is desired. These hydrogels are loaded with therapeutics and placed directly onto the 
RWM (Tsuyoshi Endo, 2005). For example, porcine type 1 collagen was crosslinked and 
loaded with a protein known to promote the survival of spiral ganglion neurons (SGNs) 
(brain derived neutrotrophic factor (BDNF)) and then placed onto the RWM. The gel 
delivered protein to the inner ear for 7 days and resulted in the enhanced survival of 




pharmaceutical delivery to the cochlea include natural polymers such as chitosan-
glycerophosphate, gelatin and synthetic polymers like siloxane-based polymers (Arnold 
et al., 2005; Lee et al., 2007; Paulson DP, 2008). The round window microcatheter is 
another method which exploits intratympanic delivery to the inner ear (S. K. Plontke et 
al., 2009). Here, a sustained release microcatheter was placed in front of the RWM via a 
typanomeatal flap and was attached to an electronic pump which was used to deliver 
dexamethasone, the therapeutic of interest. However, the use of intratympanic delivery 
was hindered in that it led to uncertainty as to the amount of drug that reaches the cochlea 
due to drug losses through the Eustachian tube in the middle ear and variations in the 
thickness and composition of the RWM itself (Pararas et al., 2012). 
     Intracochlear delivery circumvents this concern by directly accessing the cochlea via 
surgical intervention. Several microfluidic technologies have been exploited in 
intracochlear drug delivery including osmotic pumps, reciprocating microfluidic systems, 
and incorporation of microfluidic channels on the cochlear implant itself (Borkholder, 
2008). For example, mini-osmotic pumps were used in conjunction with microcannulas 
to facilitate sustained delivery of brain derived neurotrophic factor (BDNF) to the rat 
cochlea (McGuinness & Shepherd, 2005). In particular, rats were profoundly deafened 
and then chronically given BDNF or artificial perilymph (AP) for a 28 day period. At the 
end of this 28 day period, animals that received chronic doses of BDNF had a spiral 
ganglion neuron (SGN) population that was similar in histological appearance and neural 
density as compared to control animals that had not been deafened. This was in stark 
contrast with the animals which received doses of AP as the histological appearance and 




therapeutic following the deafening process. Direct fabrication of microchannels onto the 
cochlear implant itself may be used to facilitate drug delivery to the cochlea. Shepherd et 
al. developed an electrode array that could chronically deliver pharmacological agents to 
the scala tympani (Shepherd & Xu, 2002). Here, electrode arrays were connected to mini-
osmotic pumps and implanted in guinea pigs. Sustained delivery of the pharmaceutical 
agent of interest from the array was maintained for a 28 day period while stimulating the 
auditory nerve suggesting this method as a promising means of cochlear drug delivery.  
     Apart from microfluidics, several other strategies are being developed for local drug 
delivery to the cochlea including viral vectors and micro/nanoparticles. Viral vectors, or 
gene therapy has been employed in the delivery of molecular therapeutics to the cochlea 
(Husseman & Raphael, 2009; Konishi, 2008). Recent studies have focused on the use of 
adenovirus (Ad) and adeno-associated viruses (AAV) as cochlear therapeutics (Staecker 
et al., 2011). For example, a multichannel electrode was inserted into a deafened guinea 
pig that was simultaneously given a single inoculation adenovirus construct that 
contained a BDNF gene insert (Chikar et al., 2008). Electrophysiological and 
psychophysical data was collected over an 80 day time period following cochlear 
implantation. Results indicated that auditory nerve survival was enhanced in animals that 
received the adenovirus in conjunction with electrical stimulation as compared to those 
that received electrical stimulation alone. Though promising, this approach is not without 
its concerns. Most specifically, the use of a virus poses significant toxicity concerns 
related to immunogenicity and some of the vectors can be difficult to generate (Staecker 
et al., 2004). Furthermore, lack of cell targeting is an issue because vectors are randomly 




delivered to auditory neurons. Genes must be efficiently delivered to the intended target 
site in order to have the desired therapeutic impact.  
1.7. Particles as a Means of Facilitating Drug Delivery to the Cochlea 
     There are multiple ways to locally deliver therapeutics to the cochlea. The first of 
these is direct injection of the therapeutic into the cochlear space. However, the half-life 
of drugs directly injected into the cochlea is relatively short (on the order of minutes or 
hours) which limits the utility of this approach. Furthermore, when a drug is injected it is 
likely to accumulate at the site of injection rather than being distributed along the 
cochlear spiral. The preferred method is to use a drug delivery vehicle such as micro- or 
nanocarrier. This method is favored because loading a drug into a micro- or nanocarrier 
enables the sustained release of drug over time (on the order of days or weeks) which 
affords greater distribution and accumulation of the drug along the cochlear spiral 
therefore providing higher therapeutic benefit. A summary of the local drug delivery 
strategies investigated in the cochlea may be seen in Table 1.1. 
     Amongst drug delivery vehicles, polymeric micro- and nanoparticles have gained 
prominence. Several particle types have been utilized to facilitate therapeutic delivery to 
the inner ear including hydroxyapatite nanoparticles, silica nanoparticles, and polymeric 
nanoparticles (Chen, 2010). Of these, poly-lactic glycolic acid (PLGA) polymeric 
particles are particularly promising as they can be designed to meet many of the desired 
criteria for a drug delivery vehicle. These criteria include biocompatibility (PLGA is an 
FDA approved material), controlled drug release (by controlling the degradation 
characteristics of the polymer(s) utilized), tailored size and shape such that particles 




of multiple pharmaceuticals into a single particle (as a result of particle 
compartmentalization), and potential for targeted delivery (via particle surface 
functionalization).  
1.8 Objectives of This Work 
     This dissertation research focuses on the in vitro and in vivo characterization of 
multicompartmental microparticles for local delivery (via microparticle infusion) of 
therapeutic agents to the cochlea. The method of particle fabrication, 
electrohydrodynamic co-jetting, as well as the composition of the microparticles 
(compartments, materials, and incorporated therapeutics) were all selected to address 
several of the aforementioned challenges in the field. Within the broad framework of 
cochlear drug delivery, this work aims to:  
1.  Define microparticle and infusion parameters as well as post harvesting techniques 
required to enhance post infusion assessment of in vivo particle presence.   
Hypothesis 1: Microparticles can be visualized in cochlear tissue. This hypothesis 
was tested through the use of confocal laser scanning microscopy to analyze cross-
sections of cochleae infused with fluorescently labeled microparticles in ex vivo and in 
vivo guinea pig models. 
Hypothesis 2: The composition of the particle delivery background matrix will 
influence the delivery of particles to the cochlea. This hypothesis was evaluated via 
observation of in vitro particle settling behavior and particle presence in cochlear cross 
sections following in vivo particle infusion. 
Hypothesis 3: Particle porosity will impact the flow and distribution of particles 
following particle infusion. This hypothesis was assessed by quantifying distribution of 




infusion. The ability to induce increased distribution of porous particles under infusion 
flow could allow encapsulated agents to reach more regions of cells within the cochlea, 
thereby potentially improving patient outcomes. 
2. Determine if microparticle infusion will impact functional and histopathological 
aspects of cochlear health. 
Hypothesis 1:  Microparticles will be able to persist in the cochlea following in 
vivo infusion. This hypothesis was investigated by using confocal laser scanning 
microscopy, image analysis, and stereological analysis to assess the distribution and 
number of fluorescently labeled microparticles at 1 and 7 days following in vivo infusion. 
Hypothesis 2: Microparticle infusion in vivo will not inhibit the function and 
viability of cochlear cells. This hypothesis was evaluated through the use of pre and post-
infusion auditory brainstem response (ABR) thresholds and comparison of white blood 
cell infiltration and hair cell survival in treated ears when compared to untreated ears at 7 
days post infusion. 
3. Determine the in vitro release profile of particles loaded with a neuroprotective agent 
following in vivo infusion microparticles. 
Hypothesis 1:  Microparticles will be able to incorporate and sequester a relevant 
agent within a particular compartment. This hypothesis was assessed through the use of 
confocal microscopy to visualize the agent within the microparticle and determine the 
locations within the microparticle where colocalization occurred between the 





Hypothesis 2: Microparticles will be able to release the agent in a sustained and 
controlled manner in vitro. This hypothesis was tested by ultraviolet spectrophotometry 
to assess release from drug loaded particles into aqueous media at multiple timepoints. 
Hypothesis 3: Microparticle release of the agent will be detectable in the 
perilymph of animals that received in vivo microparticle infusions. This hypothesis was 
evaluated by sampling perilymph from animals infused with drug loaded particles and 
analyzing the perilymph with liquid chromatography mass spectrometry (LC-MS). 
 
1.9  Overview of the Dissertation 
 
Chapter 2 identifies key experimental design parameters for the particle delivery system. 
 
Chapter 3 determines important factors that influence microparticle persistence and 
distribution in the cochlea in vivo and evaluation of cochlear tissue tolerance of infused 
microparticles. 
 
Chapter 4 evaluates microparticle drug delivery release in vitro and in vivo.  
 
Chapter 5 concludes the dissertation and discusses future research directions based on 
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Figure 1-1. Illustration of sound processing in normal hearing. A) Sound wave 
enters the outer ear. B) Wave induces vibration of the bones in the middle ear. 
C) Bone vibration induces fluid movement within the cochlea (inner ear). D) 
Hair cells are stimulated by fluid movement and their vibrations cause 
electrical signals to be sent to the brain by underlying auditory nerve cells. 





Figure 1-2. Low magnification view of the cross-section of the guinea pig cochlea 

















                                  
Figure 1-3. Tonotopic map of the cochlea. Frequency of sounds perceived decreases in a 











   
Figure 1-4. Cross-section of cochlea with implant denoting cochlear structures (Wilson 









Figure 1-5. A cochlear implant consists of an external audio processor, implant coil, and 
electrode array. The audio processor turns sounds into signals that can be transmitted to 
the internal implant coil and converted to electrical signals. Electrical signals are sent to 









Table 1-1. Potential Strategies for Cochlear Drug Delivery 
Potential Inner Ear 
Carriers 









Mini Osmotic Pump Continuous 
delivery 
Must be refilled; Biofilm 
formation; 
basal to apex 
Viral vector Induce 
regeneration 
Induce immune response; 
toxicity  
Variable 
Gel/sponge Ease of insertion Extracochlear/Intratympanic 
application; drug 
incorporation by diffusion; 









Chapter 2                                                                                                                               
Cochlear Drug Delivery Process Design Parameter Determination 
                                                            Abstract 
The use of pharmaceuticals to treat cochlear pathologies is a well-established 
practice. Traditionally clinicians have been limited to using agents that could either easily 
be injected into the middle ear or well-tolerated systemically. These requirements have 
restricted potential patient benefit from pharmaceutical intervention, especially those 
suffering from sensorineural hearing loss and requiring cochlear implantation because 
there are several agents that may improve outcomes in implantees that are not appropriate 
for delivery by either means. Intracochlear (local) drug delivery is an alternative delivery 
strategy capable of increasing the treatment options available to physicians and patients. 
The ideal carrier for local delivery would be functionalized and subsequently attached to 
the cochlear implant and/or cochlear cells, deliver multiple drugs with distinct 
pharmacokinetics, and sustain factor release over a defined period of time.  Adequate 
distribution and ability to monitor distribution, e.g. via fluorescent probes incorporated 
into the carrier, would be important. To that end, fluorescent multicompartmental 
microparticles were evaluated to determine their utility for local drug delivery to the 
cochlea. 
     In this chapter, we characterize the feasibility of intrascalar delivery and detection of 




FDA approved biodegradable polymer and a polysaccharide via electrohydrodynamic co-
jetting. Parameters impacting particle visualization and behavior within cochlear tissue 
were investigated using ex-vivo, in vitro, and in vivo models. In ex-vivo models guinea 
pig cochlea were harvested prior to infusion with microparticles (MPs) and in in vivo 
models cochlea were infused prior to harvesting. In vitro models were used to refine the 
fluorescent intensity of microparticles and particle solution composition and determine 
the impact of porosity on particle distribution under flow. Confocal laser scanning 
microscopy (CLSM) was used to confirm particle composition and multicompartmental 
nature. CLSM was also used to visualize particles in cochlear tissue. Scanning electron 
microscopy (SEM) was used to determine the impact of tissue processing agents on 
particle integrity. Important parameters to enable particle detection in cochlear tissue 
were identified and include: fluorescent intensity, viscosity of the particle solution, and 
fixation method. Refinement of the aforementioned parameters resulted in visualization 
of microparticles in cochlear tissue from both ex-vivo and in vivo models. Particle 
integrity as indicated by a smooth surface topology was maintained following exposure to 
tissue processing agents such as decalcification solution. Further confocal laser scanning 
microscopy confirmed that the fabricated particles had multiple distinct compartments. In 
addition, in vitro assessment demonstrated that particle porosity does not impact particle 






                   2.1.1    Microparticle Design 
     It is known that the characteristics of microparticles (MPs) will either enhance or 
inhibit pharmaceutical release and degradation in their target environment over an 
extended period of time. Particle shape and size has previously been demonstrated to 
impact drug delivery, macrophage uptake, and cell uptake of particles (Champion & 
Mitragotri, 2009; Champion et al., 2008). Cell binding is size and shape limited because 
test articles must be sufficiently small as compared to a target cell. Cell uptake particles 
must have satisfactory surface area to volume (aspect) ratios to facilitate incorporation 
into intracellular spaces. In addition, size and global shape influence persistence of these 
vectors at the site of their initial attachment since these parameters determine the 
magnitude of shear forces generated against the particle and influence the likelihood that 
the vehicle will be dislodged (Patil et al., 2001). The size of target cells in the inner ear 
range from 8-20 microns in length, therefore a candidate microparticle with a diameter of 
approximately 8µm was selected as cell binding but not uptake was desired. Further, 
particles of this size are more resistant to phagocytosis by macrophages. 
2.1.2 Materials Used in Cochlear Drug Delivery 
     Both synthetic and natural materials have been explored as carriers for pharmaceutical 
or growth factors delivered to the cochlea. Synthetic materials such as poly-l-lysine 
(PLL), polylactic-co-glycolic acid (PLGA), and poly(ɛ- caprolactone) (PCL) have been 
investigated as potential drug carriers to attenuate pathological conditions of the inner ear 
(Anderson, 2009; Chen, 2010; Parker et al., 2007). These materials are relatively inert; 
however, PLGA is the only biodegradable, FDA approved polymer to be studied. 




degrade in vivo to lactic and glycolic acid. These products are then naturally eliminated 
from the body via the Krebs cycle as carbon dioxide and water (Dunne et al., 2000). 
Furthermore, the polymer degradation is tunable because by changing the ratio of lactic 
to glycolic acid, the degradation rate (weeks to months) of the polymer may be modified 
to meet therapeutic needs. Previous work has been done with PLGA particles in the 
cochlea. The Ito group utilized PLGA nanoparticles (140-180 nm diameter) loaded with 
rhodamine dye to assess drug delivery to the cochlea by systemic and local delivery 
methods (Tamura et al., 2005). Particles were fabricated by an oil-in-water solvent 
diffusion method and administered systemically by intravenous injection. Two hours 
after systemic administration, 533.8±24.8 rhodamine nanoparticles were found in the 
liver while only 0.1±0.1 particles were found in the cochlea. Twenty-four hours 
following local application of these same nanoparticles to the round window membrane 
(RWM), particle presence, primarily in the basal turn, was observed. The number of 
particles, 28.8±4.5, observed in the cochlea 24 hours following RWM application was 
much greater than that observed following intravenous administration, although still 
small for therapeutic efficacy.  
     In follow-up work the Ito group utilized micron sized particles to locally deliver 
lidocaine, a pharmaceutical agent that has been shown to suppress tinnitus, to the cochlea 
(Horie et al., 2010). Microparticles (MPs) of two sizes, Lido-L (100±3.0 µm) and Lido-S 
(5±0.5µm), were fabricated using emulsification by the homogenization-solvent 
evaporation method. Evaluation of in vitro release profiles determined that the Lido-S 
particles released the majority of their payload in a burst release that was unsuitable for 




particle. The Lido-L particles demonstrated a sustained release of lidocaine during in 
vitro study and were evaluated in guinea pigs in vivo. The greatest in vivo perilymphatic 
concentration of lidocaine achieved was 0.8µg/mL which is lower than the 10.8mg/mL 
fluid concentration required for tinnitus alleviation with local administration. In addition 
functional hearing deficits as measured by auditory brainstem response (ABR) were 
present at 7 days post-round window membrane placement of Lido-L particles.  Thus 
limited drug accumulation and negative impact on cochlear function limits the utility of 
this approach moving forward. 
     Concerns about usage of a material that forms acidic, albeit natural byproducts, in the 
pH sensitive fluid environment of the cochlea may be addressed by modulation of 
particle characteristics such as size and porosity.  For example, in in vitro dissolution 
studies with PLGA microparticles at various temperatures, including physiologic 
temperatures (37°C), found that large (greater than 50 µm) particles had a faster 
degradation rate than smaller particles (less than 20µm). (Dunne et al., 2000) The 
rationale for the observed phenomenon was that in the smaller particles (less than 20µm), 
degradation products formed within the particle diffused easily to the surface while in 
larger particles (greater than 50µm) the path to the surface of the particle was longer 
which caused slower diffusion of degradation products to the surface. During this 
reduced efflux, the prolonged presence of the degradation products induced an 
autocatalytic degradation of the remaining polymer material. Visual evidence of an acidic 
environment within degrading PLGA microspheres has been produced in the last several 
years (Fu et al., 2000). Through the use of confocal microscopy, the Langer group found 




incubation in a neutral buffer solution (pH 7.4) and the average pH within the particles 
was maintained within 3% of the buffer solution. In contrast, pH for medium sized 
particles (up to 25µm) and large particles (up to 40µm), were only within 17% and 30% 
of the buffer solution pH respectively.  By selecting a particle size of approximately 8µm 
for assessment of cochlear drug delivery, we are well below the size range of concern 
with respect to acid accumulation within particles. Furthermore by exploring the use of 
porous particles we could further protect against the development of acidic particle 
interiors. This reflects increased exchange between the particle and the incubation 
medium in which it is contained. As porosity is increased, ability to form extremely 
acidic microenvironments should decrease because degradation products would be able to 
escape more readily from the interior and the surrounding medium would have easier 
intraparticle access thereby preventing acidification of the core.  
     Examples of other synthetic materials investigated for cochlear drug delivery include 
nanoparticles consisting of a block co-polymer containing poly(ethylene glycol) block 
poly(ɛ- caprolactone) 1,1_-dioctadecyl-3,3,3_,3_-tetramethyl-indocarbocyanine 
perchlorate (DiI) and Labrafac1 WL 1349, an oil made of capric and caprylic acid 
triglycerides. Anderson et. al, investigated the delivery of nanoparticles consisting of a 
block co-polymer containing poly(ethylene glycol) block poly(ɛ- caprolactone) 1,1_-
dioctadecyl-3,3,3_,3_-tetramethyl-indocarbocyanine perchlorate (DiI), a hydrophobic 
fluorescent probe (red). (2009) Poly-ethylene glycol (PEG) chains extending from the 
surface of the particle help to prevent particle aggregation in addition to reducing 
elimination of the microparticles from the cochlea due to immune response. This in vitro 




copolymer nanoparticles (NPs) in spiral ganglion (SG) cell cultures. The authors found 
that DiI-loaded NPs were internalized into several cochlear cell types including guinea 
pig spiral ganglions, and SG glia/Schwann cells, neurons, in addition to human SG 
glia/Schwann cells. The particles were well tolerated in all the cell types studied as 
indicated by cell toxicity and viability assays. The particles studied had diameters of 
83.5±17.6 nm. One of the limitations of this study was the use of poly(ɛ- caprolactone) 
which though biodegradable, has a degradation profile on the order of years, and 
therefore would persist indefinitely in the inner ear and may not enable release of a 
therapeutic dose of agents near the time of initial implantation. 
     Zou and colleagues fabricated liquid nanocapsules (LNC) under 50 nm in diameter 
that interacted with cochlear cells and tissues. This study demonstrated that LNCs can 
pass through the round window membrane (RWM), pass the cochlear partitions, and 
address inner ear cell populationsJing Zou (2008).  LNCs were endorsed as potential 
vectors for drug delivery into the spiral ganglion cells, nerve fibers, hair cells, and spiral 
ligament. One of the limitations of this approach was that it depends on RWM 
permeability which varies from animal to animal. 
     An example of natural materials investigated for cochlea drug delivery is the alginate-
heparin beads developed by (Noushi, 2005) to release NT-3, a neurotrophin demonstrated 
to promote the survival of auditory neurons after cochlear damage. The beads were 
created by ionic gelation and incubated with NT-3 overnight for a final NT-3 uptake of 
98-99%. The authors were able to introduce 4-5 beads (0.5-1mm diameter) into the scala 
tympani via perforation of the round window and seal them into the cochlea using muscle 




survival was observed at one month and no significant inflammatory effect was found. 
The limitations of this study were potential variable drug loading and observed high burst 
release due to simple immersion of beads for NGF incorporation, and the large size of the 
beads relative to the scala (0.5 – 1.0mm) (Noushi, 2005).  Recently, Buckiová et. al 
demonstrated the transport of fluorescently labeled liposomes and polymersomes through 
the round window membrane into the cochlea in a murine animal model. Particles were 
primarily found in the spiral ganglion neurons, but were also present in the lateral wall, 
organ of Corti, and spiral limbus (Buckiová et al., 2012).  The toxicity of unloaded 
nanoparticles was assessed via auditory brainstem response and change in hearing 
threshold was observed after application of either type of nanoparticle. Nanoparticles 
were also loaded with a neurotoxic agent, disulfiram, to ascertain whether the particles 
were capable of delivering enough payload to induce a functional effect. Within two days 
of Disulfiram-loaded nanoparticle delivery, the number of spiral ganglion cells decreased 
significantly.  Within two weeks, hearing threshold shifts of 20–35 dB were present as 
detected by auditory brainstem responses. The toxicity of particle payload appeared 
limited to the intended target of spiral ganglion cells because no changes in hair cell 
morphology or function were detected following delivery of disulfiram-loaded 
nanoparticles. In this study, morphology was observed via phalloidin staining and 
functionality was assessed by otoacoustic emission recordings. The materials used to 
fabricate the nanoparticles must be considered however, because the polymersomes are 
made of polyethylene glycol-/block/-poly(ε-caprolactone) and the liposomes also contain 
polyethylene glycol, which raises concerns about the long term impact of the degradation 




nanoparticles restricts loading to one pharmaceutical per particle. Finally as with other 
drug delivery systems that rely on round window membrane permeability, the high 
inherent variability of this mode of transmission must be considered.   
     The use of nano and microtechnology for drug delivery often necessitates the dispersal 
of particles in an aqueous solution to facilitate delivery. The components of this solution 
are selected based on biological relevance or inertness in accordance with the intended 
application. The intended application will drive selection of solution components, 
however agents selected should be biologically relevant and inert. A homogeneous 
suspension may be made by vortexing, however, particle sedimentation may arise from 
differences in density between the dispersed phase (e.g. microparticles) and the 
continuous phase (e.g. artificial perilymph). Sedimentation occurs when the dispersed 
phase is more dense than the continuous phase. Thus sedimentation must be taken into 
consideration when designing a drug delivery vehicle for the cochlea.  
                               2.1.3 Delivery schemes used for cochlear drug delivery 
     The maximum rate at which a solution may be pumped into the cochlea without 
causing damage to cellular structures is 1 µL/min (Alec N. Salt & Plontke, 2005). The 
volume of a guinea pig cochlea is approximately 10µL.  The microliter volume of the 
cochlea means that even small leaks could result in the loss of significant amounts of 
both perilymph and infusion solution. Therefore delivery must include a ‘rest period” 
after infusion during which time the delivery cannula remains in place in the 
cochleostomy, to reduce efflux from the cochlea when the cannula is removed. 
Recently, the Lahann lab at the University of Michigan (Lahann, 2011) developed a 




multicompartmental microparticles. The microparticles are comprised of PLGA and 
PLGA/acetal dextran polymers. They can be fabricated in sizes ranging from submicrons 
to tens of microns and pharmaceuticals of interest may be incorporated directly into the 
polymer solution prior to jetting. A variety of shape configurations are also possible and 
the flexibility of platform in creating particles with selected characteristics is outlined in 
Figure 2-1. In this study we determined the process design parameters needed to enable 
the delivery and visualization of eight micron spherical microparticles within the cochlea. 
During the completion of this work the following hypotheses were addressed: 
Hypothesis 1: Microparticles can be visualized in cochlear tissue. This hypothesis 
was evaluated using a guinea pig animal model. Following ex-vivo and in vivo infusion, 
cross-sections of cochleae infused with fluorescently labeled microparticles were 
assessed with confocal laser scanning microscopy (CLSM). 
Hypothesis 2: The composition of the particle delivery background matrix will 
influence the delivery of particles to the cochlea. This hypothesis was investigated using 
in vitro and in vivo methods. Particle settling behavior was assessed in vitro and particle 
presence in cochlear cross sections was quantified following in vivo particle infusion.  
Hypothesis 3: Particle porosity will impact the flow and distribution of particles 
following particle infusion. This hypothesis was explored via in vitro infusion of particles 
of various porosities along a cochlear-like microchannel. Following infusion, particle 
distribution was quantified to determine if there was correlation between particle porosity 
and distanced traveled. The ability to induce increased distribution of porous particles 
under infusion flow could allow encapsulated agents to reach more regions of cells within 




                                                            2.2  METHODS 
    2.2.1 Particle Fabrication 
     Particles used in the following study were made of poly-lactic- glycolic acid (PLGA) 
or poly-lactic-glycolic acid and dextran acetal(PLGA/dex). PLGA hybrid particles 
consisted of two types of PLGA, Purasorb 5004a (MW:44 kDa) and Purasorb 5002a 
(MW: 17 kDa). Both types of PLGA had a lactic to glycolic acid ratio of 1:1. PLGA/dex 
compartments contained 25% PLGA (MW: 44 kDa) and 75% Dextran Acetal. The 
polymer dye, poly[(m-phenylenevinylene)-alt-(2,5-dihexyloxy-p-phenylenevinylene 
(MEHPV) which was visualized with the blue channel during imaging was incorporated 
into both compartments of PLGA/dextran particles for all in vivo and ex vivo 
experiments. For compartmentalization studies, MEHPV was utilized in the 
PLGA/dextran compartment while poly[tris(2,5-bis(hexyloxy)-1,4-phenylenevinylene)-
alt-(1,3-phenylenevinylene) (PTDPV) was used to delineate the PLGA only compartment 
(green channel during imaging). All particles were made by electrohydrodynamic co-
jetting (Lahann, 2011), a process which involves a side-by-side capillary needle system 
containing polymer solutions and the application of an electric field to the system. The 
field stabilizes the interface between the solutions enabling the formation of an electrified 
polymer jet of particles with multiple distinct compartments. Some of the particles 
containing PLGA/dex compartments were also incubated in an acidic solution (pH=5) for 
15 hours to facilitate pore formation on the surfaces of those compartments. Particles 
were then washed with PBS+1% Tween 20 five times to remove all acid, then filtered 
through a 10 µm filter.  After filtration, particles were centrifuged down and the PBS 
removed. A schematic of the particle fabrication process may be seen in Figure 2-2. Prior 




145mMNaCl, 2.7mMKCl, 2.0 mM MgSO4, 1.2 mM CaCl2, 5.0 mM HEPES; pH = 7.35-
7.40, osmolality = 285–300mOsm) or artificial perilymph with known percentage of 
bovine serum albumin (BSA) (ex-vivo) or guinea pig serum albumin (GPSA) (in vivo) to 
create a solution with a specific concentration (mg/mL) of particles for infusion. Due to 
the molecular weight of the PLGA/dextran used, microparticles fabricated with this co-
polymer were labeled high density (HD) particles. Further, particles made completely of 
PLGA/dextran that were not exposed to the acidic incubation were labeled high density 
control (HDOC) particles. Two types of PLGA/dex particles were exposed to acidic 
incubation. The first type of particle was one that contained PLGA/dex in one 
compartment and subsequently had pores in only one compartment and therefore was 
referred to as a high density monoporous (HDO) microparticle. The second particle type 
contained PLGA/dex in two compartments and subsequently had pores in two 
compartments, high density bi-porous (HDOB) microparticle. A schematic of the PLGA 
hybrid and high density particles is seen in Figure 2-3. When used simultaneously in 
experiments, particles fluoresced in the blue/DAPI (HDOC), green/FITC (HDO), or 
red/Rhodamine (HDOB) channels respectively as seen in Figure 2-4.  
2.2.2 Particle Characterization  
     Prior to infusion studies, scanning electron microscopy was used to visualize the 
surface morphology of the high density microparticles. Further, as visualization of the 
particles in tissue had not been attempted previously, the ability to identify particles in 
cochlear cryosections was assessed. This assessment utilized sections obtained from both 
ex vivo and in vivo infusions. The fluorescence intensity of 3 mg/ml blue & red/green dye 




Fluoresbrite) was used to assess the efficacy for the infusion protocol. In vitro, bovine 
serum albumin was used to determine the concentration of guinea pig serum albumin that 
would be needed during in vivo infusions to reduce particle settling. 
          2.2.3 In vivo Infusion  
     For in vivo infusions, Hartley guinea pigs (Charles River Laboratory, Wilmington, 
MA) were anesthetized and the temporal bone was drilled to facilitate visualization of the 
cochlea. A fine pick was then used to create a small, less than 0.2mm, fenestra in the 
basal turn of the cochlea. A micro-cannula with a silastic ball was inserted into the scala 
tympani via the cochleostomy and cyanoacrylate was used to seal the cannula in place 
(Prieskorn & Miller, 2000).  The microcannula was made from polyimide and the silastic 
ball was made from Sylgard (Dow Corning, Midland, MI).A syringe infusion pump 
(Harvard Apparatus, Holliston, Maine) was used to deliver particles to the scala tympani 
at a flow rate of 1µL/minute over 5 minutes. This rate was selected because it is the 
highest infusion rate that may be used in the cochlea without damaging cochlear cells and 
structures. In some experiments, commercially available polystyrene beads (PSB; 
Fluoresbrite) were used as a control to assess utility of the infusion protocol. Infusions 
were always performed on the left ear and the right ear was used as a contralateral 
control.  
2.2.4 Ex vivo Infusion 
     In the ex vivo infusion model, guinea pig cochleae were dissected and decalcified prior 
to particle infusion. Specimens were stored at 4°C in 0.4% paraformaldehyde (PFA) until 




syringe micropump was used to infuse 20 μL of 13mg/mL PSBs or 100mg/mL bi-colored 
MPs into the cochlea.  
2.2.5 Cochlear Dissection  
     For in vivo specimens, guinea pigs were anesthetized and euthanized by cardiac 
perfusion with 0.1M phosphate buffer followed by 4% paraformaldehyde or by injection 
of sodium pentobarbital (FatalPlus; Vortech Pharmaceuticals, Dearborn, MI). In all cases, 
secondary euthanasia was performed by transecting the aorta and the ventricle. Animals 
were decapitated and skulls were opened along the midline to facilitate removal of the 
brain. The temporal bone which encases the cochlea was removed for both the left and 
right cochlea. The bulla of the bone was identified and bone chippers were used to 
remove the excess bone to facilitate visualization of the cochlea. The malleus, incus, and 
stapes bones were also removed. A sharp probe was used to create small fenestra in the 
apex to aid infiltration of fixative and specimens were fixed in 4% paraformaldehyde for 
at least 1-2 hours prior to preparation.  
2.2.6 Decalcification and Cryoprotection of Specimens  
     Following fixation, cochleae were decalcified in a solution that is 2/3 formic acid 
(Immunocal; Decal Chemical Corporation,Tallman, NY) and 1/3 7% sucrose for 6-8 
hours. Prior to freezing, specimens were placed in aluminum container and immersed in a 
30% sucrose solution. Freezing was performed by placing the bottom of the container in 
contact with liquid nitrogen cooled 2-methyl-butane (Fisher Scientific, Pittsburgh, PA). 




 2.2.7 Cryostat Sectioning  
     Sections 14µm in thickness were collected from 0-2000µm in depth. The 0 depth was 
categorized as the first section where any portion of the cross section of the cochlear 





mounted on a microscope slide. Each slide contained 2 sections such that set of collected 
serial sections were contained on one slide. Slides were allowed to air dry for a minimum 
of one hour before being placed at -80°C until they could be mounted and imaged. 
Comparisons were made between slides from the same one hundred micron depth.  
2.2.8 Confocal Laser Scanning Microscopy 
     An Olympus confocal microscope with Fluoview software was used to visualize and 
acquire images of the particles. Particles were excited at the following wavelengths as 
appropriate for visualization: fluorescein isothiocyanate (FITC), 4',6-diamidino-2-
phenylindole (DAPI), and tetramethylrhodamineisothiocyanate (TRITC). The FITC 
channel was also used to aid the acquisition of differential interference contrast (DIC) 
images. Images were acquired with a resolution of 1024x1024 pixels. Specimens were 
mounted in Floumount (Electron Microscopy Sciences, Hatfield, PA) and coverslipped 
for imaging. The seal between the mounting medium and the coverslip was allowed to 
dry for a minimum of 2 hours prior to imaging. 
2.2.9 Fabrication of Cochlear-like Microchannels 
     Silicone two part A:B (1:10; Dow Corporation) was mixed and poured on microscope 
slide and allowed to air dry. A mask in the shape of a rectangle with a consistent 1 mm 
diameter that spanned a length of 20mm was fabricated. At the end of the rectangular 
channel, a triangular outlet was added to provide an outlet for the infused microparticle 




used to cut away the silicone to create the channel. Infusions of 1mg/mL microparticles 
(0.33mg/mL of each particle type) in 30% bovine serum albumin (BSA) were made at 
1µl/min. Microchannels were wetted with deionized water prior to infusion to facilitate 
distribution throughout the entire channel by decreasing the hydrophobicity of the surface 
and to more closely mimic the in vivo environment. Confocal images were taken 
immediately following infusion at the following points along the channel: 5, 10, 15, and 
20mm. Images were collected at 20X magnification on an Olympus Confocal Microscope 
as described above.  
2.2.10 Impact of Processing on Particle Integrity 
     Scanning electron microscopy (SEM) (Philips XL30 ESEM, high vacuum mode at 
5kV) was used to image PLGA only particles that had been immersed in one of two 
decalcification solutions, either 5% EDTA or commercially available Immunocal. 
Decalification of cochleae immersed in 5% EDTA generally takes 2-3 weeks, however, 
decalcification in Immunocal requires less than 24 hours. Particles immersed in artificial 
perilymph served as a control. Particles were immersed in the solutions from 3 hours to 
10 days. At the requisite timepoint, the respective solutions containing particles were 
centrifuged and excess fluid was aspirated. Particles were resuspended in distilled water 
and 10µL of the suspension was pipetted onto on graphite conductive coating disc 
(Electron microscopy sciences, Hatfield, PA) on top of a metal stub, in preparation for 
SEM. The suspensions were allowed to dry for 24 hours prior to sputter coating with gold 




                                 2.2.11 Impact of Processing on Particle Persistence  
     Cochleae from infusion procedures were cryoprotected and sectioned as described 
previously in sections 2.2.6 and 2.2.7. Upon removal from storage at -80°C, sections 
were permitted to air dry and were either rinsed and mounted or mounted without rinsing 
to evaluate rinsing on particle counts and distribution. 
2.2.12 Image J Analysis  
Image J software (NIH, Bethesda, MD) and the cell counter plug-in were used to 
determine the number of particles of each type present in the cochlear tissue or a cochlear 
sized microchannel. When multiple particle types were present, the color of the 
fluorescence channel emitted from the particle was used to delineate one particle type 
from another. Each type of particle was given a different counter number (i.e. green/FITC 
particles were assigned counter number 2, blue/DAPI particles were assigned counter 
number 3, etc.) to enable counts of the various particle types to be performed.   
2.3 RESULTS & DISCUSSION 
2.3.1 Particle Characterization 
     Some characterization studies utilized PLGA only particles rather than the PLGA 
dextran particles. This paradigm provided good baselines (for intensity, particle integrity, 
etc.) because the same type of PLGA was used in both particle systems. 
     The fabrication of the high density PLGA/dextran acetal particles was confirmed by 
confocal laser scanning microscopy as seen in Figure 2-5 whereby the PLGA/dextran 
compartment is indicated in the DAPI (blue) channel and PLGA only compartment is 
indicated in the FITC (green) channel. The surface morphology, including the porous 




control high density particles was visualized via scanning electron microscopy as seen in 
Figure 2-6. During initial in vivo experiments, particle settling was observed in the 
microsyringe during the time period after particle loading and flush of the cannula, but 
prior to the start of the rate controlled infusion of the particle solution into the cochlea. In 
vitro experiments, demonstrated that it took 15 minutes for particle settling to occur. It 
was determined that the viscosity of the microparticle/artificial perilymph mixture was 
too low and thereby enabled the particles to “fall-out” of solution and sit on the bottom of 
the microsyringe which reduced the number of particles delivered to the cochlea. In order 
to increase the viscosity of the background matrix used for microparticle delivery, 
albumin was added to the artificial perilymph. Albumin is a soluble protein naturally 
found in blood plasma and is biocompatible and biodegradable (Sayyed Abolghassem, 
2003). Bovine serum albumin (BSA) was used in in vitro assessments and guinea pig 
serum albumin (GPSA) was used in in vivo assessments. GPSA was used in in vivo 
assessments to minimize the immune response. During the development of the 
albumin/artificial perilymph solution, a mismatch was discovered between the percentage 
of bovine serum albumin used to prevent settling in in vitro studies and that required to 
prevent the same phenomenon with the guinea pig serum albumin in vivo. GPSA was less 
dense than the BSA, therefore larger amounts of GPSA were required to obtain an 
albumin/perilymph solution of similar viscosity. For the purpose of these studies, desired 
viscosity was not directly measured rather it was evaluated as a function of particle 
settling time. The desired time was selected based on empirical observations and 
subsequent analysis of the amount of time that elapsed between particle loading into the 




minutes and 1% particles in a 30% BSA solution was determined to have the necessary 
viscosity to keep particles in suspension. To prevent settling in 1% microparticles for the 
same amount of time with GPSA, a 55% solution was required.  
     Visualization of the microparticles once they were infused into the cochlea was crucial 
to these studies. Therefore, concentration and fluorescence intensity experiments were 
conducted to identify optimal operating parameters for both factors. Microparticle 
concentrations evaluated were 20, 40, and 100 mg/mL respectively as seen in Figure 2-7. 
The 100 mg/mL concentration yielded approximately 1.4 million particles in 5μL. 
Previous studies showing functional efficacy of stem cells on the order of 1M, indicate 
that a target of 1.4M is appropriate (Parker et al., 2007).  Initial work began with the 
100mg/mL concentration, however it was ultimately decided to switch to 15mg/mL 
particle solutions because of particle aggregation and settling at the higher 
concentrations. At a concentration of 15 mg/mL, particle counts typically ranged from 
325,000-350,000. If further reduction of particle aggregation became necessary, the 
particle surface could be modified to enable the attachment of polyethylene glycol (PEG) 
which reduces particle interactions due to steric hindrance (Fang et al., 2009).    
Initially, it was difficult to discern the PLGA microparticles within infused 
cochlear tissue. Therefore, a commercial particle, Fluoresbrite, was identified and served 
as a comparison standard in intensity studies. The Fluoresbrite beads are made of 
polystyrene and were selected because of their intense fluorescence, good dispersion, and 
similar size, 6μm, to the microparticles, 8μm. Furthermore, there was outstanding 
spectral overlap between the microparticles (excitation at 488 nm) and the polystyrene 




vehicles simultaneously for direct comparison of intensity. Additionally the commercial 
beads demonstrated outstanding visibility within cochlear tissue sections as seen in 
Figure 2-8. The amount of blue and red/green (B&R/G) dye needed for incorporation 
into dual color PLGA microparticles to provide good signal in the presence of the 
Fluoresbrite beads was also determined as seen in Figure 2-9. 
     In addition to providing a benchmark for fluorescence intensity, the non-
biodegradable Fluoresbrite beads were also used to validate the chosen surgical infusion 
protocol to ensure that it enabled effective delivery of particles to the cochlea and that 
these particles could persist in the cochlea for at least 24 hours post-infusion. Ex vivo and 
in vivo guinea pig cochlea models were used to characterize the distribution of the 
microparticles and the control polystyrene beads within cochlear tissue.  Large sections 
of intact cochlea and thin sections of cochlea were assessed. Both MPs and PSBs were 
detected in vivo and ex vivo (not shown) by 2 Photon CLSM in whole cochlear specimens 
after 24 hours as seen in Figure 2-10. Furthermore, microparticles and Flouresbrite 
polystyrene beads were both visible in cochlear cryosections of ex vivo and in vivo 
specimens at the 24 hour timepoint.  
2.3.2 Processing Studies  
     Extensive post processing of mounted tissue was required for imaging and particle 
distribution assessment. Therefore it was important to assure that some of these steps 
were not inherently damaging to the particles because they may have made counting 
difficult and confounded results. Scanning electron microscopy (SEM) (Philips XL30 
ESEM, high vacuum mode at 5kV) was used to assess PLGA particle morphology 




cryosectioning. Particle response to two types of decalcification solutions, 5% 
(Ethylenediaminetetraacetic acid) EDTA and Immunocal, a commercial decalcification 
product were evaluated.  Particle immersion in artificial perilymph served as a negative 
control. As expected, immersion in artificial perilymph did not change particle 
morphology. Furthermore, particle immersion for up to 24 hours in Immunocal and up to 
10 days in 5% EDTA also appeared to allow maintenance of particle integrity as shown 
in Figure 2-11. The surface of particles remained fairly uniform and did not experience 
dramatic changes in size.  
     Once satisfied that the microparticles were sufficiently fluorescent to enable 
distinction from tissue and that the decalcification solutions did not significantly degrade 
the particles, the impact of slide processing steps were evaluated. Washing was needed 
for specimen slides when optimal cutting temperature (OCT) compound was used as the 
cryoembedding medium for infused cochleae as this material left a white film on the slide 
and within the tissue spaces. This film impeded detection and imaging of particles by 
confocal microscopy thereby necessitating washing. There was concern that wash steps 
may, in addition to eliminating the film, remove hydrophobic particles from the tissue 
specimens. Therefore to eliminate the need to wash slides, the cryoembedding medium 
was switched to a 70% sucrose solution which dries clear, and thereby does not require 
clearing with exogenous liquid agents to visualize microparticles within the cochlear 
tissue sections.  To ascertain whether washing impacted the number of MPs observed in 
cochlear sections, particle counts were performed on cochlear cross sections exposed to 
wash steps as well as those mounted without washing. On average, 10% fewer particles 





     Initial in vivo studies did not demonstrate the presence of large numbers of particles 
within the cochlea following infusion. Post processing of cochlear tissues for 
cryosectioning and analysis involved an intracardiac perfusion of 4% paraformaldehyde 
to assure that the tissue was properly fixed. A poor cardiac perfusion revealed much 
greater numbers of particles than previously visualized, with  association of particles with 
cochlear vasculature or blood clots. Future animals did not receive a vascular perfusion 
and confirmed a much larger number of particles present in the cochlea. Non-perfused 
cochleae had an average of 400% more particles than perfused specimens. Therefore, 
animals used in all subsequent experiments were not systemically perfused with 
paraformaldehyde to facilitate fixation.  
2.3.4 Cochlear-like Microchannel  
     In addition to particle persistence, our goal was to assess particle distribution within 
the cochlea. In particular, we were to determine if different surface architectures of the 
microparticles impact their distribution within the cochlea. Our initial hypothesis was that 
increased porosity would respond to minute flow initiated by the micropump and 
facilitate infusion and distribution of the microparticles in the cochlea. To test this 
hypothesis, a small channel similar in width (1mm) and length (20mm) to the cochlea 
was fabricated and a microsyringe pump was used to infuse particles into the channel as 
seen in Figure 2-12. When used simultaneously in experiments, particles fluoresced in 
the blue/DAPI (high density control), green/FITC (high density monoporous), or 
red/TRITC (high density biporous) channels respectively. Distribution of HDOC, HDO, 
and HDOB particles within cochlear molds under experimental like conditions were 




channel. Confocal images were taken at 20X magnification at all locations and the 
number of each type of particle present was evaluated using Image J. Though 
unexpected, the microparticle surface architecture did not seem to impact the distance the 
particles traveled as seen in Figure 2-13. This finding suggests that fluid flow produced 
by the syringe pump is too small to create the laminar flow needed to enhance 
distribution.   
                                          2.4 CONCLUSIONS 
     This work has demonstrated the feasibility of visualizing multicompartmental particles 
within the cochlea and its respective tissues. In order to accomplish this work, particle 
parameters such as size, fluorescence intensity, porosity, and concentration were refined. 
Further, infusion conditions such as microparticle solution composition and delivery rate 
were considered. Finally, the impact of post infusion processing including perfusion, 
decalcification, cryoprotection, and specimen rinsing were determined. Particle 
parameters, infusion conditions, and post processing were modified when necessary to 
facilitate increased visualization of microparticles in the cochlea, thereby enabling more 








Figure 2-1. Schematic of electrohydrodynamic co-jetting set-up and the particle 
characteristics that can be controlled through the use of this fabrication process. Adapted 















Figure 2-3. Schematic of PLGA hybrid and PLGA/dextran acetal high density 
particles. White dots indicate pores within the PLGA/dextran compartments. A) 
PLGA particle comprised of two PLGA polymers of two different molecular 
weights B) High density control particle (HDOC) C) High density monoporous 










Figure 2-4. 20mg/mL infusion solution of high density microparticles (ratio of particles 
is 1:1:1 HDO:HDOB:HDOC). The fluorescence is indicative of each particle type: 











Figure 2-5. High density particles. A) PLGA only compartment B) PLGA/dextran 










Figure 2-6. Scanning electron microscopy of PLGA/dextran acetal high density 
microparticles. A) Control B) Monoporous C) Biporous. Images Courtesy of Sahar 





















                                                                                                                                         
Figure 2-7. Microparticle concentrations (mg/mL) of PLGA hybrid particles. A) 20 





       











Figure 2-8. Fluoresbrite beads within cochlear tissue. Fluoresbrite beads (green) were 
easily visible within cochlear cross-sections of the first turn. In this image beads are 
associated with auditory nerve and the spiral limbus. A) Fluorescent image with DAPI 












Figure 2-9. In vitro comparison of 3 mg/mL blue dye incorporation of MPs with PSBs. 





















































Figure 2-10. 2 Photon confocal laser scanning microscopy image (CLSM) of in 
vivo distribution of particles near round window at 24 hrs in an approximately 






















   
 
Figure 2-11. Microparticles in experimentally relevant solutions at various timepoints. 
A) Artificial perilymph at 10days B) EDTA Decalcification solution at 10days C) 
Artificial perilymph at 6 days D) EDTA Decalcification solution at 6 days E) Immunocal 








Figure 2-12. Experimental set-up of microparticle distribution within microchannel with 
cochlear dimensions. A) Syringe pump was used to dispense particles into the channels 
shown in B). Magnified view of the micropump dispensing microparticle solution into 














Figure 2-13. Particle distribution within microchannel by particle type. No difference 
was observed at any of the distances along the microchannel assessed of high density 







Chapter 3  
Particle Distribution, Persistence, and Tissue Tolerance In Vivo 
    Abstract 
     For patients with moderate to profound sensorineural hearing loss, cochlear implants 
are the treatment of choice. Increasing numbers of implant recipients have some 
remaining hearing and this hearing requires protection from the trauma induced by 
insertion. Local delivery of therapeutic agents could potentially protect remaining 
sensory cells and neuronal connections. After in vivo infusion, cochleae were harvested, 
decalcified, and sectioned to enable visualization of particles within the scala tympani 
and cochlear tissue via confocal laser scanning microscopy (CLSM). Microparticles 
persisted in the cochlea for 7 days post infusion.  Quantitative and stereological analysis 
revealed that at both 1 and 7 days post-infusion, particles were present extending from 
the cochleostomy site in the base of the cochlea primarily into the first and second turns, 
and to a more limited extent in the third and fourth turns. The particles’ impact on 
acoustic responsiveness and cell morphology was assessed at day 7 post infusion. 
Functional assessment was based on auditory brainstem response (ABR) threshold 
differences between baseline (BL) and day 7 post microparticle infusion . The majority of 
subjects did not experience a significant BL – Day7 threshold shift, defined as an 
increase of 15 or more decibels.   
     Histopathological assessment of microparticle infusion consisted of a cochlear-




Analysis of hair cell loss included individual graphical representations and statistical 
analysis.  An analysis of variance (ANOVA) was used to facilitate statistical comparisons 
between the outer hair cell (OHC) loss of treated and untreated ears at each individual 
turn. OHC loss in turn one, near the infusion site, was not significantly different between 
treated and untreated ears. In turn 2, the difference was statistically significant; however,  
average losses for both the treated and untreated ear were well under 10%, the difference 
may not be as functionally meaningful. Interestingly, turns 3 and 4 were significantly 
different when treated (left ears) were compared to non-treated (right ears), with higher 
average losses for treated ears than for untreated ears.   CD45, is a marker of white blood 
cells, and was used to assess white blood cell presence in the cochlea of infused and non-
infused ears. No difference was observed in the amount of CD45 reactivity between left 






3.1  INTRODUCTION 
                                                3.1.1 Cochlear Implantation and Concerns 
     Cochlear implants have been a benefit to individuals with hearing impairment for 
more than 30 years (Waltzman, 2006). The success of cochlear implants as an 
intervention strategy in individuals with sensorineural hearing loss has led to the 
expansion of the patient pool for implantation to include those with residual hearing. In 
this expanded pool, the remaining sensory and neural cells of the cochlea could 
experience trauma from the physical insult involved in implant insertion. Attempts have 
been made to modify physical factors involved in implantation such as the use of soft 
insertion techniques and electrodes designed to minimize structural damage. However, 
Eshraghi et al. demonstrated that these modifications have not been sufficient to prevent 
injury on the molecular level (2006; 2007). With the increase of the candidate population 
for cochlear implantation to include patients with remaining hearing, there is an urgency 
to eliminate insertion related cell death and thereby hearing losses occurring post 
implantation (Gantz 2005). Evidence indicates that optimal rehabilitation for these 
patients would result from use of electrical stimulation from the implant in the 
dysfunctional  areas of their cochleas and amplified acoustic stimulation of the portion 
with residual hearing and functioning hair cells.  This obviously requires the preservation 
of residual hearing. However, there also is evidence that benefits from electrical 
stimulation are also enhanced by preservation of residual hearing, including increased 
speech discrimination, particularly in noisy environments, and sound localization 
(Mowry et al., 2012).  




                            3.1.2 Approaches to Attenuating Implantation Trauma 
     Alternative approaches such as the delivery of pharmaceuticals to arrest the 
mechanisms leading to damage appear necessary to provide protection during 
implantation. Further, the mode of delivery is crucial to evaluating the efficacy of 
therapeutic approaches. Because of the blood-labyrinth barrier, local delivery of 
pharmaceuticals is preferred to enable accumulation of therapeutically effective doses of 
drug within the cochlea (Alec N. Salt & Plontke, 2009). With preparation of the cochlea  
for placement of the cochlear implant into the perilymph of the scala tympani, there is  an 
opportunity for local delivery of therapeutic agents that has direct clinical applicability to 
the primary site of expected trauma. The use of multicompartmental microparticle 
carriers for drug delivery in the cochlea can provide an excellent way to deliver 
therapeutics with the potential to protect residual hearing at the time of cochlear 
implantation. Factors that will determine the utility of employing the carriers for this 
purpose include the persistence and distribution of the microparticles within the cochlea. 
Delivery vehicles that can resist clearance from the cochlea and persist on the timescale 
of weeks to months are needed to provide sustained exposure to therapeutic agents.  
Chapter 2 contained studies aimed at evaluating the potential to visualize 
multicompartmental polymeric microparticles within cochlear tissue. This was an 
important first step to characterizing them as potential drug carriers to facilitate local 
cochlear drug delivery.  
     The next steps involve characterizing particle behavior and impact on the cochlea 
following in vivo infusion. This chapter describes studies to evaluate the distribution, 




pig animal model.  
          3.1.3 Rationale for Selected Approach to Attenuating Implantation Trauma 
     A guinea pig animal model was selected because of the extensive history of its use 
within auditory research, accumulated expertise in our lab, and surgical anatomy of the 
head and cochlea which facilitates preparation and microparticle infusion as compared to 
other rodent models. Multicompartmental microparticles were chosen for this study 
because of the potential to load more than one drug within a single delivery vehicle. 
Further by utilizing a system that incorporates biodegradable polymers, the timecourse, 
and rate of release of each drug from each compartment could be individually modulated 
based on the indication of the respective encapsulated pharmaceuticals. The 
biodegradability of microparticles also removes the need to surgically remove the 
particles at a later date. Microparticle distribution and persistence were assessed utilizing 
confocal laser microscopy to visualize and image fluorescently labeled microparticles 
within cochlear cross-sections. This was done at 1 and 7 days post infusion of 
microparticles into the basal scala tympani. Images were analyzed using quantitative 
counts and stereological evaluation. Stereological evaluation was incorporated into the 
analysis of particle presence to extend the evaluation of particle number beyond the 
particular sections assessed. This method of assessment allowed the projection of the 
number of particles present within the entire cochlea.  
     Cochlear functional and histopathological assessments were conducted because it 
would be desirable for any potential intervention to ameliorate residual hearing loss 
following implantation to “first do no harm”. The intended application of this 




pathology. A normal hearing animal model was used to evaluate particle impact on 
cochlear functionality, cell survival, and cell morphology. The rationale for this decision 
allowed a more straightforward evaluation and interpretation of particle impact without 
the confounding factor of deafening. The auditory brainstem response (ABR) was used to 
assess subjects’ responsiveness to pure tones at 4, 8, and 20 kilohertz (kHz). Pre and post 
infusion threshold sensitivity measures were compared to assess pathophysiology. 
Functional assessments were performed at 4, 8, and 20 kHz, because it was easily 
measurable within the research laboratory environment and were located in the more 
basilar regions of the cochlea near the site of microparticle infusion. Hair cell counts 
were made to provide quantification and enable graphical visualization of any losses of 
these important sensory cells. Binning of distances from the cochlear apex into turns 
facilitated additional analysis wherein hair cell loss per turn could be evaluated to 
identify whether any differences existed between hair cell loss in infused and non-infused 
ears. CD45 was used as an indicator of the immunogenicity of the microparticles. Infused 
and non-infused cochleae were compared for CD45 presence. Although there was a 
resident white blood cell population, increased numbers of CD45+ cells in infused ears 
indicated that our microparticle infusion was capable of initiating a foreign body response 
which could lead to scar tissue formation and even functional impairment, therefore it is 
best avoided.  
                                          3.1.4 Immune Response in the Cochlea  
     Previously, the cochlea was believed to be an immune-privileged site due to the 
presence of the blood labyrinth barrier; however, populations of resident macrophages 




2008; Shi, 2010). Though resident macrophages are present within the cochlea, the 
number of white blood cells present in the normal cochlea is small compared to those 
present after trauma. This increase occurred within hours of insult, because of  an 
upregulation of intercellular adhesion molecule 1 (I-CAM 1) expression in cochlear cells, 
which enabled the recruitment of leukocytes from the general circulation (Tornabene et 
al., 2006). These leukocytes have been identified in the cochlea with markers such as 
CD45, F4/80, and CD54. The infiltration of these cells leads to inflammation and 
fibrosis, which can cause degeneration of cochlear cell populations such as those within 
the spiral ganglion and organ of Corti (García Berrocal & Ramírez-Camacho, 2000). 
Therefore, any intervention strategy, including the use of microparticles, minimized the 
immune response of the cochlea during and after application.  
                         3.1.5 Challenges and Considerations for Cochlear Drug Delivery  
     There are several considerations and challenges concerning cochlear drug delivery. 
One, the blood-labyrinth barrier, functions similarly to the blood-brain barrier in that it 
isolates the cochlea from many of the molecules in the general blood circulation. The 
presence of this barrier makes it difficult for pharmaceuticals delivered systemically to 
enter the cochlea, let alone to accumulate in high enough concentrations to achieve 
therapeutic dosing levels (Alec N. Salt & Plontke, 2005). Conversely, the blood-labyrinth 
barrier aids in preventing systemic side effects when local drug delivery is used to treat 
cochlear pathologies. Additional challenges to cochlear drug delivery are the persistence 
and basal-apical distribution of pharmaceuticals and/or drug carriers. Distribution is an 
issue because the native fluid environment of the cochlea is static, thus the primary mode 




delivery is needed to promote the development of a concentration gradient that favors 
distribution of the therapeutic beyond the area immediate to that of the site of initial 
infusion. Clearance, the removal of pharmacologics and/or carriers from the perilymph of 
the scala tympani, is another noteworthy challenge for drug delivery to the cochlea. 
Clearance can occur due to cell binding and uptake, particularly by immune cells, loss to 
the general circulation via the spiral ligament and stria vascularis, and loss to other 
cochlear compartments such as the scala media (Salt, 2005). The ideal cochlear drug 
delivery system would be biodegradable and would deliver multiple drugs with distinct 
pharmacokinetics, sustain continuous factor release over a defined time period, distribute 
uniformly throughout the cochlea, and enable targeting of specific cochlear cell 
populations or functional attachment to the cochlear implant.  
     Any candidate vehicle for cochlear drug delivery should demonstrate good 
biocompatibility within the cochlea. Therefore the experiments outlined in this chapter 
were designed to evaluate the functional and histopathological impact of in vivo 
microparticle infusion on the guinea pig cochlea. Experiments tested the following 
hypotheses:  
Hypothesis 1:  Microparticles will be able to persist in the cochlea following in 
vivo infusion. Confocal imaging and quantitative image and stereological assessment 
were used to analyze the persistence of fluorescently labeled microparticles at days 1 and 
7 days following in vivo MP infusion. 
Hypothesis 2: Microparticle infusion in vivo will not inhibit the function and 
viability of cochlear cells. This hypothesis was investigated at 7 days post infusion by 




infused cochleae. Day 7 auditory brainstem response (ABR) thresholds were also 
compared to pre-infusion baseline measurements.  
3.2 METHODS 
                                                                3.2.1 Particle Fabrication  
     Particles used in the following study were made of poly-lactic- glycolic acid (PLGA) 
or poly-lactic-glycolic acid and dextran acetal (PLGA/dex).  PLGA (MW: 44 kDa) with a 
lactic to glycolic acid ratio of 1:1 was used and PLGA/dex compartments contained  25% 
PLGA and 75% Dextran Acetal. All particles were made by electrohydrodynamic co-
jetting. Particles containing PLGA/dex compartments were also incubated in an acidic 
solution (pH=5) for 15 hours to facilitate pore formation on the surfaces of those 
compartments. Particles were then washed with PBS+1% Tween 20 five times to remove 
all acid, then filtered through 10 µm filter.  After filtration, particles were centrifuged 
down and the PBS removed. Prior to an experiment, a known mass of particles was 
suspended in artificial perilymph (AP; 118 mMNaCl, 30 mMKCl, 2.0 mM MgSO4, 1.2 
mM CaCl2, 5.0 mM HEPES; pH = 7.35-7.40, osmolality = 285–294mOsm) or artificial 
perilymph with 55% guinea pig serum albumin (GPSA) to create a 15mg/mL 
concentration of particles for infusion. 
                                               3.2.2 Auditory Brainstem Response (ABR) 
      Animals were anesthetized with xylazine (10 mg/kg intramuscularly) and ketamine 
(40 mg/kg intramuscularly). Needle electrodes (active, reference, and ground) were 
inserted subcutaneously at the vertex and below each pinna and used to record the 
neurologic response. Up to 1024 responses were averaged for each stimulus level, with 




delivered via a transducer coupled to the external auditory canal at 4, 8 & 20kHz. Initial 
sound levels were set at 80 dB for pre- and post- infusion tests. Threshold determination 
was based on the visual detection of maximum peak–peak amplitude of the resulting 
waveforms. ABRs were given prior to infusion to enable exclusion of animals with 
abnormal hearing, and to enable detection, if present, of threshold shifts post infusion. 
                                                                   3.2.3 In vivo Infusion  
     Surgeries were conducted in a sterile environment and utilized aseptic technique. For 
in vivo infusions, Hartley guinea pigs (Charles River Laboratory, Wilmington, MA) were 
anesthetized, a post auricular approach was used to expose the temporal bone, and 
provided access to the middle ear.  The temporal bone was drilled to visualize the 
cochlea. A fine pick was then used to create a small, less than 0.2mm, hole in the basal 
turn of the cochlea 0.5mm from the round window. A micro-cannula with a silastic ball 
was inserted 0.5mm into the basal turn of scala tympani and cyanoacrylate was used to 
seal the cannula in place (Prieskorn & Miller, 2000). The microcannula was made from 
polyethylene 10 (PE10) tubing and polyimide. The silastic ball was made from Sylgard 
(Dow Corning,Midland, MI). A syringe infusion pump (Harvard Apparatus, Holliston, 
Maine) was used to deliver particles to the scala tympani at a flow rate of 1µl/minute 
over 5 minutes as seen in Figure 3-1. This rate was selected because it is the highest 
infusion rate that may be used in the cochlea without damaging cochlear cells and 
structures. Infusions were always performed on the left ear and the right ear was used as 





                              3.2.4  Cochlear Dissection for Preparation of Cryosections  
     Guinea pigs were anesthetized and euthanized by injection of sodium pentobarbital 
(FatalPlus; Vortech Pharmaceuticals, Dearborn, MI). In all cases, secondary euthanasia 
was performed by transecting the aorta and the ventricle. Animals were decapitated and 
skulls were opened along the midline to facilitate removal of the brain. Both temporal 
bones that encase the cochlea were removed. Excess bullar bone was removed to 
facilitate visualization of the cochlea. The malleus, incus, and stapes bones were also 
removed. Specimens were fixed in 4% paraformaldehyde for 1-2 hours.    
                                                  3.2.5 Preparation of Whole Mounts  
     Guinea pigs were anesthetized and ears were harvested in the same manner as those 
used for cryosection preparation with a few notable differences. Following removal of the 
middle ear bones, the apex was visualized under stereoscopic magnification and slightly 
perforated with a 28G needle to create a small hole. Then the round window was opened 
and approximately 300µL of 4% PFA was infused directly into the cochlea via the hole in 
the apex. Specimens were postfixed by immersion in 4% PFA overnight. The following 
day, cochleae were rinsed and the otic capsule, lateral wall, and tectorial membrane were 
carefully removed. Phalloidin was used to stain the modiolous as well as the attached 
organ of Corti. After rinsing to remove excess stain, the organ of Corti was dissected 
from the modiolous and each turn was mounted and coverslipped onto a microscope 
slide.  
                                                             3.2.6 Cytocochleogram  
     Phalloidin staining of the organ of Corti enabled visualization and counting of both 
inner and outer hair cells (as indicated by the presence of nuclei and/or stereocillia). The 




immersion lens and 0.19mm reticules. The most apical turn was counted first followed by 
the remaining turns in order from those closest to the apex to those farthest from the 
apex. Counts were recorded as either: all cells present, all cells absent, the number 
present, the number absent, or uncountable (e.g., folded tissue). Counts were then plotted 
using Cytogram, a custom software, and presented as percentage hair cell loss at a 
particular distance from the apex as compared to a database of normal guinea pigs (those 
not exposed to any external stimuli or agents that could induce hearing loss). The 
tracking of distance along the cochlear spiral also facilitated the correlation of areas of 
loss with known frequency maps of the guinea pig cochlea. This provided insight on 
areas that may be functionally affected by the treatment. While the graphs generated by 
the aforementioned assessment provided a visual means to qualitatively compare losses 
between animals and/or treatments, a quantitative means of analysis was required to 
determine whether significant differences existed. An analysis of variance (ANOVA) was 
performed using the statistical package for the social sciences (SPSS) software from 
IBM. A two factor model, with factor 1= ear and factor 2=turn was employed to assess 
whether any observed differences in loss were significantly different between treated and 
untreated ears and between turns. Further bonferroni post-hoc correction was used to 
account for the multiple comparisons made. The p value for significance was .05.  
                                   3.2.7 Decalcification and Cryoprotection of Specimens  
     Following fixation, cochleae were decalcified in a solution that was two-thirds formic 
acid (Immunocal; Decal Chemical Corporation,Tallman, NY) and one-third 7% sucrose 
overnight. Prior to freezing, specimens were placed in aluminum containers and 




the container in contact with liquid nitrogen cooled 2-methyl-butane (Fisher Scientific, 
Pittsburgh,PA). Specimens were wrapped in parafilm and stored at -80°C until 
sectioning. 
                                                             3.2.8 Cryostat Sectioning  
     Samples were cut into 14µm sections. For stereological samples, the cochleae were 
sectioned up to a depth of approximately 4000µm. Every 6
th
 section was collected. A 
random number generator was used to select a number between 1 and 6. The number 
generated identified the first slide for analysis in each cochlea. Thereafter, every 6
th
 slide 
was evaluated such that the slides with numerical markings of 1, 7, 13, 19, etc. were 
exhaustively assessed. A total of 61 slides were generated for each animal and 10 slides 
from each animal were assessed to ascertain particle number and distribution. For 
immunohistochemistry, up to 8 midmodiolar sections were taken from the MP infused 
cochlea of each animal. These sections were stained with CD45, a leukocyte antigen, to 
denote immune cell activity, and propidium iodide to indicate the presence of more 
general cell structures such as nuclei. Cryosections of the liver of one of the guinea pigs 
were also made for use as positive controls and negative (in the absence of primary 
antibody) controls.  
                         3.2.9 Preliminary Particle Presence and Distribution Assessment  
     Preliminary persistence and distribution assessments were conducted using 
cryosections from cochleae that had particle infusions either 1 or 7 days prior to harvest 
of the cochlea (n=3 for each timepoint). Sections from various depths of the cochlea were 
sampled for particle number. The guinea pig cochlea consists of four turns with 2 




the location of particles within cochlear cross sections was noted and their distribution 
within the cochlea determined. A cochlear cross-section and the respective turns of the 
guinea pig cochlea are shown in Figure 3-2.  
                                                           3.2.10 Stereological Analysis  
     Particle counts were performed to ascertain the approximate number of particles 
infused during the in vivo assessments. The counts were obtained by loading a 
microsyringe and dispensing 5µL at the same rate, 1µL/min, used during in vivo 
infusions. To further account for any particle settling effects, the MP solution was 
allowed to sit in the micropump for 10 minutes, the average time between solution 
loading and the start of infusion during the animal surgeries, before dispensing the 
requisite volume. Counts were made by diluting the 5µL of the 15mg/mL particle 
solution with 100µL of PBS. This diluted solution was vortexed and 5µL were withdrawn 
and counted using a hemacytometer. Counts were performed in duplicate. Once corrected 
for the dilution factor, the approximate number of particles in 5µL of a 15mg/mL solution 
was determined to be 350,000. Stereological analysis was used to determine particle 
distribution in animals infused with unloaded PLGA/dex particles (n=3) and to estimate 
the number of particles entering the cochlea at the time of infusion. In particular, the 
optical dissector method was used to systematically create image slices that contained 
particles in tissue at multiple planes within the cochlea. This method is an unbiased 
method whereby an object is counted the first time it appears in an image. A confocal 
microscope was used to acquire z-stack image series of particles within cochlear cross-
sections. The z-step size, and thereby the dissector height, was 3.6µm. Every 6th slide 




composed of green inclusion lines and red exclusion lines. The grid was superimposed on 
top of specimen images and a particle was counted if it was inside of one of the squares 
in the counting grid or in contact with a green inclusion line as seen in Figure 3-3. The 
total number particles within infused cochlear samples could be estimated through the use 
of Equation 1.  
                                      
                                                        ̅  
 
 
 (Eqn. 1) 
 
3.2.11 Immunohistochemistry 
     Specimens were prepared in the same manner as those for the cytocochleogram, 
except the duration of post fixation was 2 hours rather than 12. Then the same protocol 
was followed as outlined in decalcification and cryoprotection. Midmodiolar sections, 12  
in total, were selected from 2 of the animals used for the collection of Piribedil exposed 
perilymph in vivo. These sections were assessed with CD45, a leukocyte antigen, to 
determine the extent to which particle infusion induced a local immune response. 
Sections from contralateral control ears and the liver from one of the guinea pigs (in the 
absence of primary antibody incubation) served as negative controls. Cryosections of the 
liver were used as positive controls in the presence of CD45 primary antibody. The 
specimens were pre-treated with 0.3% Triton X-100 in PBS for 15 min followed by PBS 
rinsing (3x5 min).  Each section was blocked for 1 hour with 5% goat serum/ and 
permeabilized for 30min with 0.3% Triton with 5% goat serum and incubated with a 
primary antibody for CD45 (AbdSerotec MCA1130 (mouse anti-guinea pig), and PBS 




hydrated chamber. The following day, samples were rinsed 2x10 minutes with PBS prior 
to a 75 minute incubation in the secondary antibody solution containing Alexafluor 488 
goat anti-mouse and PBS (1:250). Plates were rinsed 2x10 minutes in PBS. Next samples 
were incubated in propidium iodide (Sigma) (1:1000 in PBS) for 5 minutes. Propidium 
iodide staining of nuclei was used to delineate inner ear tissues, providing a visual 
reference for the location of inflammatory cells within the section. After rinsing in PBS 
3x5 min, specimens were mounted, covered with glass coverslips, and stored in the dark 
at 4°C until viewed. 
3.3 RESULTS & DISCUSSION 
                                                         3.3.1 Particle Persistence and Distribution 
     The creation of PLGA/Dex particles with distinct polymeric compartments enabled 
the characterization of the aforementioned particle system for drug delivery, specifically 
cochlear drug delivery. The immune response in the cochlea was initiated within 24 hours 
after insult. Previous work has shown that the functional hearing of animals/guinea pigs 
exposed to transient stimuli such as light noise or surgery can recover after one week 
(Puel et al., 1998). Therefore, animals were preliminarily assessed at 1 and 7 days post 
microparticle infusion to observe both particle persistence and distribution. Additionally, 
the impact of the microparticles on the functionality and histopathology of the cochlea 
was assessed on day 7.  
     On day 1 following microparticle infusion, untargeted unloaded particles were 
distributed in the cochlea as shown in Figure 3-4.The majority of the particles were in 
the first turn of the cochlea (88±17%), followed by the second turn (10±2.0%) and the 




due to the relatively few numbers of particles found in each turn alone. The considerable 
aggregation of particles in the first turn was not unexpected as the first turn was the site 
of infusion and there was negligible flow in the cochlea. The dispersion of particles to 
other turns relies primarily upon diffusion and the small flow induced by the micropump. 
On day 7 following microparticle infusion, untargeted unloaded particles were distributed 
in the cochlea as shown in Figure 3-5. Similar to day 1 post infusion, the majority of the 
particles were located in the first turn of the cochlea (94±17%), followed by the second 
turn (6±2%) and the third and fourth turns (0%). Statistical analysis (student t-test) 
demonstrated that there was not a significant difference in the persistence and distribution 
of particles within the cochlea between day 1 and day 7. This indicated that particles 
which survived acute clearance (washout via eustachian tube, immune response, etc.) 
within the first 24 hours, were able to remain in the cochlea for an extended time period. 
This population of particles would be the ones responsible for delivery of therapeutics to 
the cochlea. To that end, an estimate of the number of particles remaining was necessary.   
                                   3.3.2 Estimation of Total Number of Persisting Particles 
     In order to facilitate an estimation of particle number, it was necessary to use the 
analysis method, stereology which utilizes random, systematic sampling.  The manner in 
which samples were collected to facilitate stereological analysis was quite stringent and 
therefore did not enable the retroactive analysis of the samples discussed in section 3.3.1. 
No statistically significant difference between particle persistence and distribution in day 
1 and day 7 specimens was found in the initial groups of animals assessed. Therefore, 
stereological analysis was performed on a new set of animals (n=3) at 7 days post 




distribution profile to the previous samples as seen in Figure 3-6 and the average number 
of particles persisting after 7 days was 20,000±4000. No particles were found in the 
contralateral ear, indicating that unintended effects on the contralateral ear from diffusion 
of the delivery vehicle via cerebrospinal fluid need not be a concern with this system. In 
order to put the estimated number of particles persisting in the cochlea according to 
stereological analysis in perspective, the total number of particles infused were 
determined. The starting number of particles in 5μL of a 15mg/mL solution was 
determined to be 350,000. Therefore, approximately 5.8% of untargeted particles were 
retained in the cochlea following infusion. Though this percentage was small, the utility 
of delivery from particles in this scenario was dependent on the dose of drug needed for 
therapeutic level and the extent to which the drug was able to be incorporated (weight %) 
into the particles. The incorporation and release of Piribedil from the multicompartmental 
microparticles will be experimentally outlined and discussed in chapter 4, the next 
chapter of this dissertation. Further the low percentage observed could be a consequence 
of the sample processing required to generate the particle cross-sections used in the 
analysis. During the infiltration of the decalcifying solution and/or the cryoprotection 
solution, particles located in the fluid spaces could be displaced, meaning that only 
particles closely associated with the lining of the cochlear chambers would remain for 
analysis. Therefore, it is possible that non-adherent particles were simply “washed out” of 




                                     
3.3.3 Microparticle Impact on Cochlear Function, Cell Survival and Cell 
Morphology 
     To determine the impact of these particles on cochlear health, ‘health’ was defined in 
terms of both cochlear cell/tissue appearance and the functional performance of the 
cochlea following microparticle infusion. With respect to appearance, the presence or 
absence of hair cells and immune cells was evaluated. Hair cells function as 
mechanotransducers in the cochlea and enable the fluid movement induced by sound 
waves to be converted into electrical signals that can be interpreted by the brain. These 
cells are sensitive to damage from both chemical and physical means and their absence 
impairs the hearing cascade. To determine whether the infusion protocol and/or the 
composition of the particles and/or infusion solution had a deleterious effect on hair cells, 
hair cell counts were made and plotted as a cytocochleograms. Cytocochleograms 
provided a visual representation of areas of missing hair cells and the location of these 
cells relative to the apex and base of the cochlea. Loss was indicated as a percentage 
missing in the current animal as compared to a database of normal animals that have not 
been exposed to conditions that would impact their hearing. Based on previous studies, 
an area was considered normal if the hair cell loss occurred intermittently and was 20% 
or less. In addition, in the Hartley strain of guinea pig used in these studies, it is not 
uncommon to have animals that have large amounts of hearing loss in the apical third of 
the cochlea. This is sufficiently far from the lower sixth of the cochlea where the particles 
were infused to enable the determination of the impact of particle delivery on hair 
cells/hair cell viability. Two of the animals used for cochlear health assessment were 




infused animals had hair cell losses in all rows of less than 20% in the areas adjacent to 
the site of infusion as seen in Figure 3-7.  The 2-factor analysis of variance (ANOVA) on 
OHC loss determined that both ear and turn losses were significant with a  p-value below 
the α=.05 level in treated ears, with those in higher turns demonstrating greater losses. 
Subsequent analysis was performed in which comparisons were made between the OHC 
loss of treated and untreated ears at each individual turn as seen in Figure 3-8.  OHC loss 
in turn 1, near the infusion site, was not significantly different between treated and 
untreated ears. In turn 2, the difference was statistically significant at .001, however, as 
average losses for both the left and right treated ear were well under 10%, the difference 
may not be as functionally meaningful. Interestingly, turns 3 and 4 were significantly 
different when treated (left ears) are compared to non-treated (right ears). This seems 
unusual in that it is known from the distribution studies conducted previously, that the 
particles were primarily located in the first and second turns. It is possible that the 
differences seen are related to an increase in intracochlear pressure induced by the 
surgical method or the viscosity of the background delivery solution formed from 
artificial perilymph and guinea pig serum albumin. To alleviate potential pressure 
changes due to displacement of native perilymph during infusion, an outlet hole could be 
drilled. In this manner, an exit other than the cochlear aqueduct is provided to facilitate 
removal of excess fluid from the perilymphatic space.  
     Auditory brainstem responses (ABRs) were used to assess the hearing of animals pre- 
and post-infusion. Pre-ABRs were given to select only animals with behaviorally normal 
hearing (particularly in the lower two-thirds of the cochlea; the upper third was beyond 




infusion. The assessment of baseline hearing also provided a basis for comparison to 
ABR results following infusion to assess particle impact on hearing. Post-infusion testing 
was conducted at the same three frequencies, 4, 8, and 20kHz as the pre-test. If the 
intensity level required for the subject to detect the stimulatory tone at any of the 
frequencies changed, then a threshold shift occurred. Hearing was considered to have 
worsened if the sound intensity needed for the subject to detect the stimulatory tone was 
15 or more decibels higher than in the pre-test. This value was selected because it has 
been shown to be outside the bounds of normal experimental variation (depth of 
transducer insertion, etc.) and, therefore indicative of an actual functional change in 
hearing capacity. As seen in Figure 3-9, following infusion, three out of five animals had 
hearing within the normal range as compared to their pre-infusion values which is 
indicated by the threshold shift. One of the animals, NAN 20, demonstrated a threshold 
shift (15dB) at one frequency, 20kHz. Another animal, NAN 22, demonstrated threshold 
shifts at both 4 and 8kHz. The gross anatomy of NAN 22 correlates well with observed 
functional losses as fluid was present in the middle ear of this animal and excess fluid 
makes it more difficult for sound to be transmitted, particularly at the lower thresholds. 
Since the cytocochleogram of NAN 22 demonstrated minimal hair cell loss, functional 
deficits at the lower frequencies were likely the result of conductive hearing losses due to 
the presence of the middle ear fluid.  Therefore, microparticle infusion was well tolerated 
in four out of five animals with only one animal NAN 20 displaying functional and 
histological losses. Further, the number of white blood cells present in treated ears was 
comparable to that seen in the untreated ears indicating that at 7 days post infusion, the 




3.4  CONCLUSIONS 
     This work has demonstrated the feasibility of delivering multicompartmental 
microparticles to the cochlea. Specifically it has characterized the in vivo persistence, 
distribution, and drug release from the chosen particle system. Particles were maintained 
in the cochlea for at least seven days. The impact of particles on cochlear functionality 
was minimal and no increase in infiltration of immune cells cochlear cell survival was 
observed. Further, cell survival and morphology were well maintained in the areas of the 
cochlea with high numbers of particles. An increase in the number of animals for study of 
the in vivo functional and histological assessments is necessary to provide definitive 


































Figure 3-1. Photographic image of the experimental setup for the MP infusion. 
Intrascalar delivery of microparticles at a rate of 1µL/min is facilitated through the use of 
































Figure 3-2. Example of cochlear cross section with delineation of the 












Figure 3-3. Example illustration of inclusion/exclusion grid overlayed on images to 
facilitate stereological analysis. Pluses indicate objects that would be counted as present 
while objects with minuses would not be counted. A) Magnified view of a small cluster 
of objects associated a single cell of the inclusion/exclusion grid. B) View of a cluster of 
objects within the larger framework of the inclusion/exclusion grid (Slomianka)  C) 
Application of grid to microparticle infused cochlear cross-section. Particles with yellow 
crosses would be counted while particles touching the red exclusion line (1) and particles 


































Figure 3-4. Distribution of unloaded microparticles observed 1 day after in vivo infusion. 
(A) 3 dimensional projection of the particles near the round window of the cochlea 
wherein the basal to apical direction is represented as positive in the x-z plane (B) 
Distribution of particles within the four turns of the guinea pig cochlea where turn 1 is the 





































































Figure 3-5. Distribution of unloaded microparticles 7 days after in vivo infusion (A) 3 
dimensional projection of the particles near the round window of the cochlea wherein the 
basal to apical direction is represented as positive in the x-z plane (B) Distribution of 





























































Figure 3-6. Particle distribution of unloaded microparticles observed 7 days after in vivo 
infusion. Distribution of particles within the four turns of the guinea pig cochlea where 


















































Particle Distribution in Infused Cochlea: 7 Days 
































       











Figure 3-7. Cochlear hair cell death as represented by cytocochleograms (graphical 
representation of hair cell loss) at day 7 post infusion for guinea pigs (n=5) receiving 5μL 
of microparticles. The regions of ABR functional testing as well as the cochleostomy site 
have been indicated along the x-axis. In all animals hair cell loss near the cochleostomy 














Figure 3-8. A graphical depiction of the OHC loss as a function of ear (treated/left vs. 
non-treated/right) and turn at 7 days post MP infusion. ANOVA analysis with α=.05 
found that turn (p=0.00) and ear (p=0.00) were both significant. The differences between 



































Figure 3-9. Cochlear function 7 days post MP infusion as represented by auditory 
brainstem responses. For all animals, threshold shift (difference between pre and post 
infusion thresholds) at 4, 8, and 20 kilohertz are shown. A threshold shift greater than 15 
dB is indicative of a change in an animal’s hearing. At the majority of frequencies across 





































Figure 3-10. CD45 presence in treated and untreated cochleae.  Resident white blood 
cells may be in the normal cochlea and no differences are seen in the number of these 
cells present at 7 days following MP infusion. Leukocytes cells are identified as nuclei 
(red) whose surface/cell membrane is positive for CD45 (green). 

















     Chapter 4                                                                                             
Microparticle Release of Anti-Excitotoxic Agent In Vitro and In Vivo 
         Abstract 
 
     Drug delivery to the cochlea is challenging because of issues related to poor drug 
accumulation, particularly from systemic delivery. Drug accumulation is needed to 
enable pharmaceutical concentrations within the cochlea to reach the levels required to 
provide therapeutic efficacy. However, cochlear implantation and the additional 
pathology experienced post-implantation by patients with residual hearing provide an 
excellent opportunity to utilize local drug delivery technology to address a significant 
clinical problem. This approach could increase patient benefit from implantation while 
minimizing the effects of pharmaceutical agents on other parts of the body.  
     To investigate the utility of using multicompartmental particles for intracochlear drug 
delivery, porous PLGA/dextran acetal microparticles were fabricated for in vitro and in 
vivo studies of drug release from microparticles. During jetting, Piribedil (a 
pharmaceutical demonstrated to reduce pathology from excessive neuronal stimulation in 
the cochlea) was solubilized in the PLGA contained in the PLGA-only compartment of 
the microparticle. Confocal microscopy imaging revealed both the incorporation and the 
sequestration of the Piribedil within the PLGA-only compartment of the PLGA/dextran 
acetal microparticles. Ultraviolet (UV) spectrophotometry was then used to characterize 
the in vitro release profile of the Piribedil from monoporous and biporous microparticles 




were observed in the release profile of monoporous particles as compared to biporous 
particles. This latter finding provides independent secondary confirmation of the 
successful incorporation of the Piribedil solely within the non-porous PLGA-only 
compartment. In vivo assessment of perilymph (inner ear fluid) by liquid chromatography 
mass spectrometry (LC-MS) revealed that Piribedil release from biporous particles was 
detectable at 7 days post infusion. Further, in vivo Piribedil concentration reached 







     The previous chapters evaluated microparticle visualization, persistence, distribution, 
and impact on cochlear health in ex-vivo, in vitro and in vivo systems.  In this chapter the 
encapsulation and release of a relevant therapeutic, Piribedil, from the 
multicompartmental microparticles is assessed both in vitro and in vivo. Piribedil was 
selected as a pharmaceutical of interest because one possible mechanism involved in 
neural cell death following cochlear implantation is excitotoxicity.  This excitotoxicity 
results either from inner hair cell apoptosis leading to deterioration of the inner hair cell-
auditory nerve (IHC-AN) connection or excessive glutamate release from the IHC onto 
the IHC-AN synapse causing bursting of auditory nerve processes (A. A. Eshraghi, and 
T. R. van de Water, 2006). Piribedil is an FDA approved pharmaceutical that has 
previously been shown to act as an anti-excitotoxic agent in the cochlea (d'Aldin, 1995). 
The classification of Piribedil as an FDA approved drug, would likely hasten the time to 
clinical application and was a consideration in its selection for this study. In addition, 
Piribedil has an innate fluorescence in the 200 to 300 nanometer wavelength range which 
would allow detection of the drug within the polymer via confocal microscopy in in vivo 
studies and UV spectrophotometry in in vitro release studies.   An additional approach 
was necessary to enable the assessment of in vivo particle release since native perilymph 
is a volume limited and potentially biologically complex fluid. Therefore, liquid 
chromatography mass spectrometry (LC-MS) was chosen because of the enhanced 
sensitivity and specificity needed to detect Piribedil in the microliter quantities of native 
perilymph obtained from in vivo sampling.  The sensitivity of this assay is increased by 
the incorporation of mass spectrometry which is capable of measuring analytes even at 




of drug present in the scala tympani was unknown and difficult to predict due to potential 
loss via clearance to the bloodstream or other cochlear compartments, we selected a 
method of analysis that would enable detection of Piribedil even at very low 
concentration. In addition, increased specificity was provided by the use of mass 
spectrometry in that compounds are not only distinguished by their retention time, but 
also by their mass and the pattern in which they fragment inside the mass spectrometer.    
     Encapsulation and sequestration of Piribedil within the multicompartmental 
microparticle was first performed. Once done, in vitro assessments of release were 
performed to create a release profile of Piribedil from the microparticles at various 
timepoints. This profile defined the extent to which Piribedil release from the 
microparticles could occur in the controlled, sustained manner required for intracochlear 
drug delivery. Further in vivo testing of Piribedil containing microparticles was 
performed to assess whether particles could release detectable and therapeutic amounts of 
Piribedil in perilymph and surrounding target cochlear tissues.  
                                            4.1.1 Anti-Excitotoxicity in the Cochlea 
     Anti-oxidants, corticoids/anti-inflammatory agents, and anti-excitotoxic agents have 
all been explored as potential pharmaceutical interventions for inner ear pathologies. Of 
the three classes, anti-oxidants have been the most widely investigated because of their 
demonstrated ability to preserve hair cells from trauma. Because of the focus on hair 
cells, anti-excitotoxic agents have not been as extensively explored. The use of this class 
of therapeutic could complement hair cell sparing strategies by sparing neurons which are 
also critical components of the inner ear hearing cascade. Therefore, an anti-excitotoxic 




establish this treatment paradigm was Piribedil, a dopamine receptor agonist. In the 
presence of increased neural activity, NMDA receptors, which are blocked by 
magnesium under normal conditions, become responsive to the release of the 
neurotransmitter glutamate. As a result of this increased responsiveness, an excitotoxic 
environment can be induced wherein auditory neurons are overstimulated causing their 
ion channels to open excessively as seen in Figure 4-1. Excessive opening of the ion 
channel can lead to increased calcium influx and ultimately neuronal calcium overload 
and cell death (Mark et al., 2001). 
     A strategic approach in the field has been to attenuate excitotoxicity by preserving 
inner hair cells (IHCs) and subsequently the inner hair cell auditory nerve (IHC-AN) 
connections and neurons (Le Prell, 2007).  Successful reconnection of neuronal processes 
with IHCs following insult was demonstrated in noise studies by (Puel et al., 1998), as 
long as the IHCs were maintained, leading to the assumption that the presence of IHCs 
indicated the presence of functional IHC-AN connections, as seen in  
Figure 5-1. Outline of experiment to determine efficacy of local Piribedil delivery in 
response to trauma such as noise. The duration of each phase of the experiment is 
indicated as well as the timing of functional assessments.  However, more recent studies 
by (Kujawa, 2009) demonstrate that significant losses of IHC-AN connections can be 
observed even when IHCs are preserved, indicating that the reconnection previously 
observed may not be as efficient as initially thought. 
     Prior studies by (d'Aldin, 1995) using 6-hydroxydopamine and ischemia to challenge 




lateral efferents from the auditory brainstem. The authors found that this regulation was 
made possible by axodendritic synapses between the lateral efferents and the afferent 
peripheral processes of the auditory neurons in contact with the inner hair cells. 
Specifically, this study demonstrated that dopamine may be involved in inhibitory 
regulation at the synaptic connection between inner hair cells and auditory neural 
processes. As a dopamine receptor agonist, Piribedil should inhibit the synapse 
connection between inner hair cells and auditory neurons, thereby reducing excitation 
without inducing serious side effects such as hearing loss. In the study by (d'Aldin, 1995), 
the authors found that intracochlear delivery of Piribedil prevented the swelling and 
bursting of peripheral processes otherwise induced by transient ischemia. In another acute 
by d’Aldin study evaluating Piribedil, (1995) demonstrated that a 10-minute infusion of 
1mM of free drug reduced the compound action potential (CAP) amplitude after a 
continuous 130 dB SPL pure tone noise exposure (6 kHz, 15 min) without impacting the 
cochlear microphonic (hair cell) potential. This finding by d’Aldin indicates that the 
treatment provided improved IHC-AN connection survival following insult without 
significantly impacting hair cell survival (1995).  
4.1.2 Drug Delivery: Local vs. Systemic 
     The use of local drug delivery to the inner ear is more desirable than systemic 
approaches primarily due to cochlea features such as the labyrinth-blood barrier, which 
has a similar function as the blood-brain barrier and limits the passage of molecules from 
the blood circulation to the cochlear compartment. As compared to systemic delivery, 
local delivery also reduces the potential for “side effects” of the drugs acting on other 




the site of interest, and provides more control over concentration at the site of interest. 
Therefore, one of the goals of this project is to develop clinically relevant and effective 
local delivery systems for therapeutic agents into cochlear fluids. Local delivery of 
pharmaceuticals from a carrier is preferred over direct injection of drugs into the cochlea. 
The rationale for this preference is the desire to have an increased concentration of the 
pharmaceutical agent available to cochlear cells for an extended period of time. 
Therapeutic agents injected directly into the cochlea have short half-lives—minutes to 
hours—resulting in decreased availability and primary accumulation of the drug near the 
basal turn of the scala tympani, the common site of injection. Drug delivery interventions 
utilizing continuous pharmaceutical release results in greater drug accumulation in the 
cochlea and increased distribution along the cochlear spiral (S. K. Plontke, et al, 2008). 
Therefore, sustained delivery from days to weeks will be necessary to reach maximum 
therapeutic benefit and this outcome cannot be achieved by a single injection during 
cochlear implantation. Sustained delivery of neurotrophic factors has previously been 
achieved through the use of microcannulas and mini-osmotic pumps. The pumps are 
capable of dispensing solutions at a programmed rate with one of the primary constraints 
on the duration of use being the volume of the pump. (Miller, 2007) delivered brain 
derived neurotrophic factor (BDNF) and fibroblast growth factor 1 (FGF1) for 26  days to 
the cochlea of deafened guinea pigs via the use of an osmotic minipump and a cannula 
inserted into the scala tympani. The authors were able to demonstrate that continuous 
combined factor delivery resulted in increased maintenance of spiral ganglion neurons 




     The locations of the minipump and cannula are a cause for concern. The minipump 
was implanted in a subcutaneous pocket beneath the scapulae and the cannula was 
affixed to the dorsal skull using methyl methacrylate (Miller, 2007). Though this is an 
acceptable delivery method in the lab environment, translation of such a strategy to the 
clinic would be difficult since the components are not biodegradable and would 
ultimately need to be removed, at minimum requiring minor surgery. In order to 
eliminate this concern, there are two delivery approaches that can be used singlely or 
combined that are not dependent on the prolonged use of osmotic micropumps and 
cannulas to enable continuous drug administration. One approach is to deliver drugs from 
biodegradable microparticles placed into the fluids prior to placement of the prostheses. 
The other is to deliver therapeutics from biodegradable microparticles attached to the 
surface of the silicone housing used to encase cochlear implant electrodes.   
     4.1.3 Drug Delivery and Release Assessment 
     A common target of drug delivery to the cochlea is the perilymph of the scala 
tympani, making this compartment a common sampling site for determination of 
pharmaceutical concentration in the cochlea.  The perilymph is in contact with the 
basolateral membrane of the scala media and exchange of fluids between the scala 
tympani and the scala media where the organ of Corti is located occurs. Two important 
parameters that must be considered when quantification of intracochlear drug release is 
desired include the sampling method and the volume of fluid available for sampling. The 
scala tympani, however, is also in contact with the cochlear aqueduct, which leads to the 
brain and contains cerebrospinal fluid. This cerebrospinal fluid can “leak” into the 




sample and lowers the measurable concentration of the released therapeutic. In previous 
studies that measured drug concentration in perilymph, the vast majority obtained the 
sample from the scala tympani of the basal turn by perforating the round window 
membrane or otic capsule (Arnold et al., 2005; Bird et al., 2011; Shayanne A. Lajud & 
Samudra Sanyal, 2013).  Many of these studies have also documented almost immediate 
and considerable leakage of cerebrospinal fluid into the scala tympani under these 
conditions. More recently a sampling procedure whereby perilymph is taken from the 
apical portion of the scala tympani, which is located at a greater distance from the 
cochlear aqueduct, has been developed and enables the collection of higher purity 
perilymph samples (A. N. Salt et al., 2012). Furthermore, there are only 10 µL total fluid 
(perilymph and endolymph) in the guinea pig cochlea. Of this volume, only 4.7µL is 
from the scala tympani. Even employing the apical sampling method, only the first 2 µL 
collected is considered to contain pure perilymph (perilymph without any cerebrospinal 
fluid). Therefore, complete elimination of CSF is not possible if the entire fluid volume 
of the cochlea is required for analysis; however, a correction factor can be employed to 
account for this dilution if apical sampling is performed. The minute amount of fluid in 
the cochlea generally requires that the entire fluid volume of the cochlea be collected in 
order to enable assessment by liquid chromatography-mass spectrometry (LC-MS) or 
enzyme-linked immunoabsorbent assay (ELISA), as these techniques have minimum 
volume requirements because the initial volume is further diluted during analysis.   
4.1.4 Rationale for Drug Co-Release in the Cochlea 
     Because the target population for this intervention are cochlear implantees, it should 




patient outcomes post-surgery. Some of these factors include closeness of the electrodes 
to auditory neurons, inhibition of scar tissue formation around electrodes, and inhibition 
of bone ingrowth/ossification of the scala tympani.(Stöver & Lenarz, 2009). Several 
options for pharmaceutical intervention in inner ear pathologies have been explored, 
including anti-oxidants, corticoids/anti-inflammatory agents, and anti-excitotoxic agents. 
Anti-excitotoxic agents have received the least attention despite the opportunity for 
synergistic benefit provided by treating hair cells and auditory nerve, both of which serve 
as crucial parts of the inner ear hearing cascade, and thus were selected for this study 
wherein the in vitro release profile of particles loaded with a neuroprotective agent and 
drug concentration in perilymph following in vivo infusion of agent loaded microparticles 
will be determined. The hypotheses addressed were: 
Hypothesis 1:  Microparticles will be able to incorporate and sequester a relevant 
agent within a particular compartment. This hypothesis tested through the use confocal 
imaging to visualize the colocalization of the inherent fluorescence of the pharmaceutical 
agent with that of the polymer dye used to specify a specific microparticle compartment. 
Hypothesis 2: Microparticles will be able to release the agent in a sustained and 
controlled manner in vitro. This hypothesis was investigated by monitoring the release of 
an inherently fluorescent pharmaceutical from the microparticles into aqueous media over 
a two week time period using ultraviolet spectrophotometry. 
Hypothesis 3: Microparticle release of the agent will be detectable in the 
perilymph of animals that received in vivo microparticle infusions. This hypothesis was 




assess the amount of drug released from infused microparticles into the perilymph of a 
guinea pig cochlea. 
4.2  METHODS 
                                              4.2.1 Particle Fabrication 
     The following study uses particles made of poly-lactic-glycolic acid (PLGA) or poly-
lactic-glycolic acid and dextran acetal (PLGA/dex).  A light-emitting polymer, Poly[(m-
phenylenevinylene)-alt-(2,5-dihexyloxy-p-phenylenevinylene (MEHPV), was also 
incorporated into the PLGA and PLGA/dex compartments to facilitate particle 
visualization via confocal microscopy. PLGA (MW: 44 kDa) with a lactic to glycolic 
acid ratio of 1:1 was used and PLGA/dex compartments contained 25% PLGA and 75% 
Dextran Acetal. Electrohydrodynamic co-jetting was utilized to fabricate all particles. 
Particles containing PLGA/dex compartments were also incubated in an acidic solution 
(pH=5) for 15 hours to facilitate pore formation on the surfaces of those compartments. 
Particles were then washed with PBS+1% Tween 20 5 times to remove all acid, then 
filtered through 10 µm filter.  After filtration, particles were centrifuged down and the 
PBS removed. Prior to an experiment, a known mass of particles was suspended in 
artificial perilymph (AP; 118 mMNaCl, 30 mMKCl, 2.0 mM MgSO4, 1.2 mM CaCl2, 5.0 
mM HEPES; pH = 7.35-7.40, osmolality = 285–294/300mOsm) or artificial perilymph 
with 55% guinea pig serum albumin (GPSA) to create a 15mg/mL concentration of 
particles for infusion. 
4.2.2  In Vitro Piribedil Loading and Release 
     The PLGA-Dex particles were fabricated as discussed previously with one important 




(drug to polymer in one compartment) prior to jetting. After jetting, Piribedil- loaded 
particles as seen in Figure 4-3 were lyophilized and stored until preparation for use. The 
same preparation protocol used for unloaded PLGA-Dex particles was then followed. For 
release studies, 0.4 milligrams of Piribedil-loaded particles were incubated inside a 
permeable membrane exposed to 40 milliliters of phosphate buffered saline (PBS)+1% 
Tween at 37°C for a two-week period. Samples for drug content assessment were 
performed in triplicate and collected by removing 1 milliliter volumes from the solution 
at various time intervals. The concentration of drug in the samples was determined using 
a UV spectrophotometer to measure absorbance between wavelengths of 200nm and 
300nm. Standards were created from serial dilutions of a mass of 5 milligrams of 
particles suspended in 20 milliliters of phosphate buffered saline (PBS). A standard 
calibration curve to enable the detection of unknown concentrations of Piribedil for the 
following concentrations was made and assessed: .0025 mg/mL, .005 mg/mL, .0125 
mg/mL, .0375 mg/mL, and .05 mg/mL. The linearity was maintained between 0 and 0.2 
millimolar and the correlation coefficients were greater than .991. The total amount of 
drug released was calculated for each time point. The release profile of each particle was 
expressed as a percentage according to Equation 1 as follows:  
         
                             
                  
     (Eqn. 1) 
The values obtained were plotted against time to enable characterization of the phases of 
particle drug release, from burst release to sustained release and plateau.                                  
                           




     For in vivo infusions, Hartley guinea pigs (Charles River Laboratory, Wilmington, 
MA) were anesthetized and the cochleae were accessed as detailed in section 3.2.3. A 
5µL bolus volume of the Piribedil loaded particles was delivered at a rate of 1 µL/minute. 
The cannula and syringe pump used to facilitate delivery were the same as those 
described in section 3.2.3.  
4.2.4 In Vivo Perilymph Sampling 
     Sampling of the perilymph for pharmaceutical agents as described by Salt et.al and 
seen in Figure 4-4 was undertaken just prior to animal termination.  Guinea pigs were 
anesthetized with xylazine (10 mg/kg intramuscularly) and ketamine (40 mg/kg 
intramuscularly). The apex of the cochlea was visualized by a ventrolateral approach and 
the top two apical turns are cleared of mucosa. Once the apex is dry, a thin layer of 
cyanoacrylate adhesive (vet bond) was placed over the area of the apex designated for 
perforation. Then a “cup” was formed by adding several layers of silicone (Kwik-Cast) to 
the outer edges of this area, leaving approximately a 100µm central portion with only the 
thin layer of cyanoacrylate covering it. In this region, a surgical pick was used to create a 
small fenestra and escaping perilymph was collected using a microcapillary tube 
(Drummond, P1549). A total of up to 10µL of perilymph was collected from each animal. 
In instances where less than 10µL were collected a micrometer was used to measure the 
length of the fluid column within the microcapillary and a conversion factor of 
0.24µL/mm based on the total length (41mm) of the microcapillary was used to 
determine sample volume. After collection, the perilymph was dispensed from the 
microcapillary into an eppendorf tube, centrifuged for 2 minutes, and flash frozen in 




Following sampling, animals were euthanized by cardiac puncture and cochleae were 
removed. 
4.2.5 Analysis of In Vivo Microparticle Drug Release 
     Liquid chromatography-mass spectrometry (LC-MS) analysis was performed to 
determine the Piribedil concentration in perilymph samples. The use of LC allows 
separation of the pharmaceuticals of interest from a biologically relevant background 
matrix (native or artificial perilymph) and mass spectrometry enables detection at very 
low concentrations. The extraction solvent contained 997.5 µL acetonitrile + 2.5 µL Acar 
mix. Six standards were made with increasing nanomolar concentrations of drug from 0-
3000 nanomolars. Standards were prepared by spiking native or artificial perilymph with 
3µM stock Piribedil solutions that had been diluted with the extraction solvent. 
Experimental samples obtained from animals exposed to Piribedil-loaded microparticles 
were mixed with extraction solvent and vortexed followed by 5-minute incubation at 4°C. 
The vortex/cooling cycle was completed a total of two times prior to centrifugation of the 
samples at 15,000 rpm and 4°C for 5 minutes. The sample supernatants were transferred 
to autosampler vials with inserts for LC-MS analysis. The instrumentation used for 
analysis consisted of an Agilent 1200 RRLC coupled to an Agilent 6410 Triple Quad 
LC/MS.  Analyte peaks were resolved with the use of a Waters Xbridge C18 (50 mm x 
2.1mm, particle size 2.5µm) column.  
     The liquid chromatographic conditions were as follows: mobile phases: A = 5mM 
ammonium acetate, adjusted to pH 9.9 with ammonium hydroxide; B = acetonitrile; flow 
rate: 0.25 mL/min; and injection volume: 2 µL. The gradient began at 25% B and 




holding 100% for 3 minutes. Then it was returned to 50%B and re-equilibrated for 4 
minutes thereby resulting in a total run time of 12 minutes/injection. The mass 
spectrometry source conditions were: gas temp: 325° C, gas flow: 10 L/min, nebulizing 
pressure: 40 psi, and capillary voltage: 4000V. All mass spectrometry readings were 
collected in positive ion mode. 
     Though the total volume of perilymph in the cochlea is 10µL, the volume of 
perilymph in the scala tympani, the chamber into which the particle solution is infused, is 
only 4.7µL (Thorne M et al., 1999). Cochlear fluid space dimensions for six species 
derived from reconstructions of three-dimensional magnetic resonance images. The 
balance of the remaining fluid is from the cerebrospinal fluid therefore a simple 






:_ (Eqn. 2) 
 
4.3 RESULTS & DISCUSSION 
4.3.1 Incorporation of Piribedil into Microparticles and Sequestration 
     Piribedil has poor solubility (less than 0.1 mg/mL) in aqueous solution (M. Demirel  R. 
H. Müller, 2001), however, it also has an inherent fluorescence detectable by UV 
spectrophotometry as well as confocal lasers. The aforementioned fluorescence enables 
Piribedil to be visualized within the polymer matrix of the microparticle after fabrication 
by excitation and emission in the red wavelength range. In the dextran/polylactic glycolic 
acid (PLGA/Dex) particles, Piribedil was only incorporated into the PLGA, therefore it 
should only have been visible within the PLGA compartments of the microparticle.  




(CLSM), the sequestration of the Piribedil into the PLGA-only compartment was 
confirmed, as seen in Figure 4-5. The PLGA-only compartment appeared green due to 
the incorporation of MEHPV into the polymer matrix, and the PLGA/Dex compartment 
appeared blue due the incorporation of PTDPV, thus enabling visualization of the 
separate compartments post-jetting. Furthermore, overlay of excitation of the 
microparticle within the red channel resulted in the PLGA-only compartment appearing 
yellow due to the overlap of the green fluorescence from the polymer and the red 
fluorescence from the Piribedil. No change in appearance occurred in the PLGA/dex 
compartment when an overlay of excitation of the microparticle within the red channel is 
made (such as the appearance of a purple color, which further allows confirmation of the 
sequestration of Piribedil following microparticle fabrication.)  
4.3.2 In Vitro Release of Piribedil from Microparticles 
     The visualization of the Piribedil with CLSM confirmed the presence of the 
pharmaceutical within the microparticle and enabled release studies to be conducted to 
characterize in vitro release profiles and in vivo cochlear fluid concentrations following 
infusion of drug loaded microparticles. The in vitro release profile of the Piribedil from 
monoporous and biporous multicompartmental particles is shown in Figure 4-6. The 
initial release from the microparticles in the first 24 hours following incubation was 
around 20%. A sustained release profile was evident between sampling days 2 and 9 
before particle release plateaus around day 14. Over a 14-day time period, the high 
density monoporous and high density biporous particles averaged a cumulative release of 
their initial drug content of 69.2% and 71.3%, respectively. There was no significant 




cumulative totals. This result provided additional confirmation of Piribedil sequestration 
in the PLGA-only compartment because that compartment is the same in both particle 
types. The only way that a difference in release could be observed would be if the drug 
had leached into the PLGA/dextran compartment where the porosity differences could 
then have an impact. If that were the case, the biporous particles would be expected to 
have a faster release profile since pores increase the available surface area for interaction 
between the polymer, which degrades by hydrolysis, with the aqueous environment.  
4.3.3 In Vivo Perilymphatic Piribedil Concentration 
     Based on the in vitro particle release profiles and consideration of the time to achieve 
therapeutic release of Piribedil, the 7-day post infusion timepoint was selected to perform 
perilymph sampling to ascertain in vivo concentration of Piribedil. Initially, collection of 
perilymph samples was attempted in a total of 6 animals; however, due to technical 
difficulties encountered during collection, only 4 samples could be used for analysis. The 
total volume of fluid collected ranged from 5-10.2 µL. Piribedil was detected in all 
analyzed samples. The aforementioned variability in sample fluid volume also correlated 
with variability in quantified Piribedil concentration as seen in Table 4-1. Two of the 
collected samples, NAN 30 and NAN 32, had volumes allowing the assumption that 
most, if not all, of the approximately 2 µL of pure perilymph was captured. These 
samples were within therapeutic range both before and after applying the correction 
factor. Therefore, a minimum collection volume was imposed upon the additional 
samples collected in order to measure in vivo Piribedil concentration. In the subsequent 
round of collection, 4 additional samples met the volume criteria and were assessed for 




Piribedil. Though the institution of a minimum volume did lead to decreased variability 
in the concentration of Piribedil in the perilymph, some of the variability that remains in 
the apparent perilymph concentration could be the result of the variability in the number 
of particles that persist in the cochlea post infusion. Therefore, one approach to improve 
the amount and consistency of Piribedil available 7 days post infusion would be to 
incorporate targeting ligands for cell populations in the cochlea such as the epithelium. 
These ligands could be attached to particles, thereby increasing the number of particles 
retained in the cochlea and subsequently the amount of drug available for release. 
Perhaps more importantly the remaining particles would be retained at therapeutic target 
sites, thus likely increasing efficacy.  Alternatively, the surface of the particles could be 
modified to enable attachment to the cochlear implant itself. This approach would also 
provide increased control over particle number and persistence within the cochlea.  
 
4.4 CONCLUSION 
     Piribedil was successfully incorporated into the PLGA-only compartment of 
PLGA/dextran particles. In vitro assessment provided confirmation of the sequestration 
of Piribedil because no difference was observed in the release profile of biporous 
particles when compared to monoporous particles. Further, the controlled and sustained 
release of Piribedil from the multicompartmental microparticles was demonstrated. In 
vivo assessment of perilymph from animals infused with Piribedil-loaded particles 
demonstrated that the microparticles could release detectable amounts of drug for at least 
7 days. In addition, the amount of Piribedil detected in cochlear fluids at the 




measurable release of drug from the multicompartmental microparticles is possible and 









4.5  FIGURES & TABLES 
 
Figure 4-1. Excitotoxicity cascade indicating the chain of events caused by cochlear 
trauma that can lead to excitotoxicity and loss of inner hair cell auditory nerve synapses. 






Figure 4-2.  Image illustrating the site of connection between the inner hair cell and 
auditory neuronal processes. Trauma such as noise and potentially cochlear implantation 
may lead to the degeneration of these connections even when the inner hair cell is still 

































Figure 4-3. A) Schematic of Piribedil-loaded biporous particle. PLGA/Dex compartment 
(blue) and separate PLGA compartment (green) wherein Piribedil (red) is incorporated 
into the PLGA-only compartment. White circles represent pores. B) Scanning electron 





Figure 4-4. Schematic of the steps involved in the apical sampling procedure: (A) Use 
ventral approach to expose cochlea and remove mucosa from apical turns; (B) Apply a 
thin layer of cyanoacrylate glue to the bone over apical turns; (C) Construct a cup using 
two-part silicone around the cochlear apex. Apply silicone very thinly to the region to be 
perforated. Once ready to sample, perforate the apex with a fine pick; (D) Collect all fluid 
efflux from the apical perforation site into a calibrated capillary tube (Alec N Salt et al., 
2007). 










      
 
      
Figure 4-5. Biporous MPs loaded with Piribedil A) PLGA/Dex.(blue) compartment       
B) Distinct PLGA (green) and PLGA/Dex.(blue) compartments C) Piribedil in PLGA 

























































Table 4.1. Perilymph Volumes and Piribedil Concentrations from in vivo Sampling 
 
Specimen Volume (µL) Concentration (nM) Corrected Concentration (nM) 
NAN 30 10.2 339.23* 736.20* 
NAN 32 9 106.04* 207.57* 
NAN 41  8.4 207.41* 370.68* 
NAN 44  7.22 205.73* 316.04* 
NAN 45 7.1 192.01* 290.06* 
NAN 34  6.88 223.43* 327.07* 
NAN 31 6 13.68 17.47 
NAN 29 5 44.48 47.32 
Average 7.45 166.50 289.05 
Standard 
Deviation 
1.67 106.13 222.84 
 
 





 Chapter 5                                                                                                    
Conclusions & Future Directions 
 
5.1 CONCLUSIONS 
    This dissertation characterizes multicompartmental microparticles and their use as 
vehicles for inner ear drug delivery. This work provides the first evaluation of multi-
release particles for local drug release in the cochlea for both in vitro and in vivo 
environments; it defines the hurdles to efficacious use of these drug carriers for 
modifying inner ear function; and it identifies a research pathway that may enable clinical 
translation of these drug carriers in the efficacious treatment of inner ear disease.   
     In Chapter 2, we ascertained preferred design and infusion parameters for local drug 
delivery in the cochlea. Parameters were classified as preferred if their modulation led to 
an increase in the visualization of the microparticles within cochlear tissues. 
Multicompartmental microparticles fabricated via electrohydrodynamic co-jetting were 
evaluated in ex-vivo, in vitro, and in vivo systems. The identified preferred parameters 
from ex-vivo and in vivo assessment were associated with particle design, particle 
infusion protocol, or tissue processing and post harvesting. In particular, for particle 
design, the fluorescence intensity of particles was improved by increasing the amount of 
polymer dye incorporated during particle fabrication. The most important parameter of 
the infusion protocol was the composition of the background solution used to suspend the 
particles to facilitate delivery. Finally tissue processing procedures such as the use of 




commercial agent with decreased time to decalcification also improved visualization of 
microparticles following infusion. In vitro infusion experiments revealed that 
microparticle porosity did not impact the distribution of microparticles within a cochlear-
like microchannel.  
     In Chapter 3, in vivo microparticle persistence, distribution, and impact on cochlear 
function and histopathology were assessed. Confocal microscopy of cochlear cross 
sections demonstrated the presence of microparticles at 1 and at least 7 days post 
infusion. Microparticles were located primarily in the basal and second turns. Neither 
particle distribution nor number changed with increased time indicating that if particles 
avoided clearance in the first 24 hours following infusion, they persisted for functionally 
and therapeutically relevant durations. Further, stereological analysis was used to 
estimate the total number of microparticles present at 7 days post infusion throughout the 
entire cochlea which provides baseline for assessing future modifications aimed at 
increasing particle persistence post infusion. This development also informs aids 
understanding of dosing requirements pharmaceuticals that could be used based on 
percent drug incorporation into particles and particle persistence following infusion.  
Microparticles were not detected in the contralateral ear at 1 or 7 days. Functional 
analysis with auditory brainstem response demonstrated that infusion of blank particles 
could be delivered with no negative impact the hearing and no effect on hair cells. 
Analysis of variance assessment (ANOVA) of hair cell counts revealed that the number 
of hair cells present in the first turn of treated cochleae were similar to those of non-
treated cochleae. Interestingly, the number of hair cells present in infused cochlea were 




despite minimal particle presence. Importantly, microparticle infusion did not induce an 
immune response as indicated by the comparable numbers of CD45 positive (white 
blood) cells present in infused cochleae when compared to non-infused contralateral 
cochleae.   
      In Chapter 4, pharmaceutical release from the multicompartmental microparticles 
was evaluated both in vitro and in vivo. In vitro release of Piribedil, an anti-excitotoxic 
agent, was evaluated by UV-spectrophotometry and demonstrated that the microparticles 
were capable of sustained release on the order of weeks which would be suitable for 
intracochlear drug delivery. Liquid chromatography mass spectrometry (LC-MS) analysis 
of perilymph obtained 7 days after infusion of Piribedil loaded particles identified the 
pharmaceutical at detectable levels in all samples. For the first time, we demonstrated the 
release of therapeutic levels of a pharmaceutical from an intracochlear particle system. 
Prior to assessment of in vivo drug concentration, the incorporation and sequestration of 
Piribedil into the appropriate microparticle compartment was confirmed via confocal 
laser scanning microscopy. In addition, the porosity of particle compartments did not 
impact the sustained release profile in vitro.  
     Multicompartmental particles fabricated by electrohydrodynamic co-jetting had not 
previously been utilized in biological tissues or an animal model. Therefore this research 
has resulted in the refinement of an innovative platform for use in vivo with great 
potential for expanding the selectivity and utility of cochlear drug delivery. Since 
porosity did not induce differential particle distribution, future efforts should focus on 
particle shape, rather than porosity, as a design feature with the potential to impact 




Piribedil release profile from MPs in vitro, and in the future it could be informative to 
assess in vivo perilymph samples at various timepoints to determine how well the in vivo 
profile correlates with that obtained in vitro. Although, Piribedil was used as the test 
article for this work, other anti-excitotoxic agents could be used. Further these agents 
could target other facets of excitotoxicity beyond cell responsiveness to glutamate such as 
the rate of glutamate re-uptake (recycling) or glutamate production. This would aid in the 
determination of the most efficacious component of the excitotoxicity cascade to target in 
reduction efforts.  
                                           5.2 FUTURE DIRECTIONS 
5.2.1 Drug Delivery in the Cochlea  
     The use of pharmaceutical intervention to ameliorate cochlear pathologies and/or their 
associated symptoms has been in place for several decades, however, with notable gains 
in technology, particularly the fabrication of micro- and nanoparticles, the possibilities 
for local drug delivery to the cochlea are expansive. Use of micro- and nanoparticles is 
also capable of extending the agents used for local treatment to include growth factors, 
peptides, DNA, and siRNA. Further micro- and nanotechnologies can be used to facilitate 
monitoring of the cochlea in real time for assessment of characteristics such as cochlear 
blood flow and/or be utilized as monitors of enzymatic activity. Particle platforms will be 
an integral part of the future of cochlear drug delivery because they can provide local and 
targeted delivery that will reduce patient side effects. In addition, particle systems will 
provide scientists with important information concerning the microenvironment present 





5.2.2 Assessment of Efficacy of Microparticle Drug Delivery in Noise Trauma Model 
In Vivo  
    This dissertation described the development and characterization of the 
multicompartmental microparticles for cochlear drug delivery. The experimental model 
used for this work was exclusively a normal hearing ear. The next steps in the short term 
evaluation of the multicompartmental microparticles should investigate the utility of 
microparticle drug release in a traumatized ear model. Inner ear trauma may be induced 
by chemical, mechanical, or acoustic stimuli. In future studies an acoustic or “noise” 
model should be studied as a proof of principal pathological model to determine whether 
local delivery of anti-excitotoxic pharmaceuticals from the microparticles can provide 
protection to inner hair cell-auditory connections. Acoustic stimuli are suggested because 
its use provides an opportunity to induce selective hearing loss (in a particular region). 
The outline for the experiment may be seen in  
Figure 5-1. The experiment involves noise exposure of normal hearing guinea pigs (as 
determined by auditory brainstem response) 7 days following intrascalar placement of 
microparticles with or without test pharmaceuticals. Day 7 post infusion was chosen for 
noise exposure because of the in vitro release data for the Piribedil loaded particles which 
demonstrated that at day 7 sufficient Piribedil had been released and remained likely to 
provide therapeutic effectiveness. Further, previous research has shown that ABR 
thresholds of surgical animals have generally recovered so that they are comparable to 
pre-infusion values by day 7. Animals will be exposed bilaterally to a 122 octave band 
noise (OBN) for 3 hours. Without intervention, this exposure should cause permanent 
functional and histological damage, including damage to the afferent peripheral processes 




     At 5 days post microparticle infusion and 14 days post-noise ABRs will be used to 
assess hearing to define surgical and noise induced changes from baseline hearing 
sensitivity. Post-life assessment will include immunohistochemistry of hair cell loss and 
loss of inner hair cell-auditory nerve (IHC-AN) connections. These evaluations will be 
performed on cochlea harvested 14 days following noise exposure. We will obtain hair 
cell counts from the Phalloidin staining and generate cytocochleograms to determine the 
loss of hair cells and the distribution of the losses in the cochlea based on our noise 
trauma model. Standard analysis of variance (ANOVA) testing will be used to determine 
whether significant differences (in the number of synapses present occurs between 
groups.     
     Confocal laser scanning microscopy will be used to acquire z-series images of inner 
hair cells and their associated IHC-AN puncta. The IHCs will be visualized with a 
Phalloidin (f-actin) stain and the puncta will be labeled with C-terminal Binding Protein 2 
(CtBP2) which is a protein that occurs at the presynaptic terminal of the inner hair cells 
before interfacing with auditory nerve. The z-stacks will be used to provide a quantitative 
assessment of the number of CTBP2 immunolabeled “puncta” per inner hair cell at 3 pre-
determined regions of interest (ROI) along the cochlear spiral as seen in Figure 5.2 and 
Figure 5-3. The aforementioned regions of interest are categorized by frequency and 
collected at 0.4, 4, and 20  kilohertz. Frequency values were selected to span the range of 
the distribution of particles as determined by the distribution studies outlined in chapter 3.  
Following noise exposure, we would expect, Piribedil infused ears to have increased 
IHC-AN connections as compared to those ears that received blanks or were untreated. 




Piribedil is used as an anti-excitotoxic agent in this study and is not known to impact hair 
cell survival.  
     A pilot study (n=3) with Piribedil loaded particles was conducted that indicated the 
following: the chosen noise exposure induced large losses of outer hair cells in both 
treated and untreated ears as indicated by the cytocochleograms in Figure 5-4. These 
findings correlate with functional losses present in the auditory brainstem responses of 
the pilot animals as shown in Figure 5-5. In addition, there were large spikes of inner 
hair cell loss in several of the ears, both treated and non-treated, which is undesirable.  
Therefore, the noise exposure parameters will need to be modified to produce a damage 
profile that does not include losses of inner hair cells. The number of inner hair cell 
auditory nerve synapses remaining were indicated by CTBP2 staining as seen in Table 5-
1. The number of CTBP2 positive cells were comparable between treated and untreated 
ears at lower frequencies although a difference existed at 20 kHz, the higher frequency 
assessed wherein untreated ears contained increased amounts of CTBP2 staining. 
However, more animals are needed to implement the full experimental design as seen in  
Figure 5-1. Additionally, in the long term, it would be worthwhile to investigate the 
efficacy of microparticle release in a cochlear implant trauma model because that would 
most closely mimic the intended clinical application. The same general experimental 
outline could be applied, however, the trauma that occurs on day 7 would be implant 
insertion.  Alternatively, the experimental design could be modified such that particle 
infusion occurs at the same time as implantation. Further, the number of treated animals 
may need to be increased due to increased variability of damage induced by manual 




5.2.3 Assessment of Growth Factor Release: GDNF   
     One of the potential benefits of using the chosen polymeric microparticle system for 
drug delivery is the availability of functional groups allowing surface modification with 
growth factors and attachment of targeting ligands. Several growth factors have been 
identified as contributing to the maintenance or regrowth of peripheral nerve processes 
following trauma, including neurotrophic growth factors such as brain derived 
neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and glial derived neurotrophic factor 
(GDNF). In the near future, studies should investigate the benefit of providing acute and 
sustained delivery of a biologically active neurotrophin in addition to an anti-excitotoxic 
drug such as Piribedil. In particular, GDNF has been shown to promote spiral ganglion 
cell survival both in vitro and in vivo in addition to attenuating spiral ganglion neuron 
(SGN) and hair cell loss after ototoxic insult. Since GDNF is capable of influencing hair 
cell survival, a microparticle incorporating Piribedil and GDNF could be used to 
simultaneously facilitate the preservation of hair cells, spiral ganglion neurons, and inner 
hair cell-auditory nerve connections in cochleae exposed to trauma.  Both in vitro and in 
vivo assessments should be employed to assess the feasibility and utility of attachment of 
GDNF onto the microparticles. 
    Confocal laser scanning microscopy would be used to confirm the attachment of 
GDNF onto the surface and within the porous cavities of the microparticles. GDNF 
would be attached to the surface of and within particles because incorporation into 
multicompartmental particles as fabricated in this dissertation could denature the protein. 
A similar strategy was used by Tan et al. to release brain derived neurotrophic factor on 




be created to encapsulate the GDNF, albeit utilizing different polymer components.   
Further, GDNF concentration on the microparticle surface will be quantified with an 
enzyme-linked immunosorbent assay (ELISA) utilizing antibodies to human GDNF to 
assess the concentration of GDNF in the incubation solution prior to and following 
microparticle incubation. In addition, in vitro and in vivo release of the GDNF from the 
microparticles will also be determined by ELISA.  For in vitro release sturdies, a profile 
will be developed over a 30 day period. The timepoint for assessment of release in vivo 
would be determined by the time it takes to achieve therapeutic concentrations in vitro.  
     We would expect the release of GDNF from the microparticles to occur primarily by 
diffusion. Therefore the release profile should contain a small initial “burst” release 
followed by a steady increase in release until a plateau is reached.  This work would help 
extend the utility and variety of therapeutic approaches that could be investigated using 
the multicompartmental microparticles as a delivery platform.  
5.2.4 Efficacy of Local Delivery from Multi-Agent Loaded Microparticles In Vivo: 
Piribedil/GDNF and Piribedil/Anti-Oxidant 
    Following characterization of in vitro release, in vivo efficacy studies could be 
performed. In addition to hair cell and CTBP2 counts, spiral ganglion counts would also 
be made to determine whether the release of GDNF increased the density of neurons 
present within the modiolous and auditory nerve following noise exposure. The density 
and growth/regrowth of peripheral processes would also be assessed.  The addition of the 
aforementioned assessment would also necessitate an increase in the duration of the 




neurons occurs on a slower timescale than the disappearance of the inner hair cell 
auditory nerve connections.  
    In addition to the bursting of peripheral processes, cochlear insult can induce the 
formation of reactive oxygen species (ROS). Though this dissertation, and the future 
work highlighted previously, have largely focused on preservation of inner hair cell 
auditory nerve connections, an investigation of combinatorial therapy with the addition of 
anti-oxidants may provide more efficacy in ameliorating induced pathology than either 
type of drug alone. This premise is based on the recognition that such a treatment 
paradigm attacks both pre-synaptic and post-synaptic components of the inner ear hearing 
cascade, and ROS formation has been found to play a role in excitotoxicity (Mark et al., 
2001). Anti-oxidant therapy is an appropriate complimentary treatment strategy because 
it aids in the prevention of hair cell death which has a secondary impact on the viability 
of auditory neurons. Of particular interest would be vitamins A, C, and E, anti-oxidants 
that function as free radical scavengers which help eliminate the reactive oxygen species 
(ROS) generated by cochlear trauma. In the presence of ROS, hair cells undergo 
apoptotic cell death which leads to the deafferentation of auditory nerve, subsequent 
peripheral process degeneration, and eventually spiral ganglion cell death (Le Prell, 2007; 
Maruyama et al., 2007; Sha, 1999). This outcome is detrimental as the presence of viable 
spiral ganglion neurons capable of responding to stimulation is crucial to the efficacy of a 
cochlear implant. While anti-oxidant therapy has been demonstrated to have a positive 
impact on hair cell survival after insult, it has not been shown to significantly impact 




    Experiments would characterize the pathophysiology of the cochlea following 
permanent threshold shift (PTS) inducing noise exposure. Efficacy of local delivery of 
Piribedil/GDNF or Piribedil/ACE loaded microparticles on auditory brainstem responses 
(ABRs) will be taken to provide a clinically relevant functional measure of both the 
pathology induced by the insult and assess the effectiveness of these interventions and 
this model. The utility of the intervention is further assessed by comparison of spiral 
ganglions (SGNs), hair cells (HCs), and inner hair cell auditory nerve (IHC-AN) 
synapses in treated and untreated groups.  
    We anticipate that the addition of local release of GDNF from the microparticles will 
reduce the loss of HC, IHC-AN connection, and SGNs induced by the noise exposure as 
compared to Piribedil only particles. We also anticipate that addition of local release of 
Vitamins A, C, and E will reduce HC losses induced by the noise as compared to both 
Piribedil only and GDNF/Piribedil particles. These studies would provide insight on 
whether synergistic effects could occur between treatments of different classes of 
therapeutics and establish multicompartmental microparticles as a valuable drug delivery 
vehicle for such studies.   
5.2.5 Microparticle Attachment to Cochlear Implant 
     The use of multicompartmental microparticles for therapeutic cochlear drug delivery 
is dependent upon the number of particles that persist following perfusion. The work in 
this dissertation demonstrated that untargeted particles persist in the cochlea, even though 
the number was a small fraction of the number delivered. To increase particle persistence, 
particle delivery strategies that do not involve infusion of a free particle suspension 




particle number and resistance to clearance. Thereby, an extension to the studies 
described in the main body of this dissertation includes the surface modification of 
microparticles to enable the attachment of particles to a substrate such as the silicone 
housing of a cochlear implant. This attachment would limit particle clearance via 
macrophage uptake and loss to the general circulation or down the cochlear aqueduct.  
    The microparticles that will be used in this study will be attached to the 
aforementioned substrates via covalent or click chemistry strategies. Particle orientation 
and appearance after attachment and the extent of particle coverage of implant housing 
will be assessed with scanning electron microscopy. Further the strength of particle 
attachment will be assessed with adhesion testing and confocal laser scanning 
microscopy. The impact of microparticle attachment on microparticle release would also 
be investigated in vitro.  This study would allow increased control of microparticle 
distribution, including enhanced access to upper turns of the cochlea, and dosing because 
particles could be uniformly distributed along the implant and the number/concentration 
of particles immobilized on the surface could be easily determined thereby enabling more 
precise predictions of dosing as long as the amount of drug loaded within particles was 
known. In addition, more precise control of dosing could enable agents with higher 
therapeutic concentrations to be used efficaciously in cochlear drug delivery that would 
not otherwise be viable options.  
    The work outlined in this dissertation as well as that proposed or in progress under 
future directions, enhance the development of strategies for drug delivery to the inner ear. 
This was accomplished through the evaluation of the first multi-release particle system 




drug delivery in the cochlea were identified such that microparticles could be visualized 
and were able to persist for at least 7 days in cochlear tissue. In addition, for the first 
time, the release of therapeutic levels of a pharmaceutical from an intracochlear particle 
system was demonstrated. These accomplishments will serve as a springboard for the 
design and evaluation of multi-release therapeutic systems which may ultimately 
maximize the benefit of cochlear implantation for individuals with residual hearing. 
Benefit will be from the combined use of therapeutically preserved low frequency 
acoustic hearing and CI enabled high frequency electrical hearing. Specifically 
implantees should expect to have increased speech discrimination in noise (such as 
talking in a crowded restaurant) and increased detection of sound pitch (which is required 
to recognize song instrumentals in the absence of words). This means that one day a 
young woman will have less anxiety about being at a crowded party and a young man 






5.3  FIGURES & TABLES 
 
 
n ABR/IO Treatment Noise ABR/IO Sacrifice 
Days 
 
Pre days 0-21 Day 7 Day 5/21 Day21 
Anti-excitotoxicity 
group 
      Group 1 8 Yes Unloaded MPs  Yes Day 5/21 Day 21 
Group 2  8 Yes Piribedil loaded 
MPs 
Yes Day 5/21 Day 21 
       Total n 16 
      
Figure 5-1. Outline of experiment to determine efficacy of local Piribedil delivery in 
response to trauma such as noise. The duration of each phase of the experiment is 























Figure 5-2. Schematic representing inner hair cell-auditory nerve (IHC-AN) regions of 
interest (ROIs) for C-Terminal Binding Protein Assessment in the guinea pig cochlea. 3 
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Figure 5-4. Cytochochleograms of noise exposed animals from efficacy pilot study 
(n=3). Left (treated) and right (untreated). Black arrows indicate the approximate location 
of a particular frequency along the cochlea as well as the cochleostomy/infusion site. 
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Figure 5-5. Threshold shifts from auditory brainstem responses for efficacy animals. A) 

























































































Table 5-1. Average Counts of Inner Hair Auditory Nerve Connections from Efficacy 
Experiment  
Specimen ROI 1 (0.4kHz) ROI 2 (4kHz) ROI 3 (20kHz) 
Treated Ears 
NAN 36 12.5 
 
17 12.3 
NAN 37 11.2 14.5 13.7 
NAN 39 14.5 13.1 10.7 
Treated Average 
     
12.7 14.9 12.2 
Untreated Ears 
NAN 36 12.5 15 15.5 
NAN 37 11 15.6 19 
NAN 39 11.8 13.8 19.3 
Untreated 
Average 
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